annual report 2013 year ended march 31 2013 song real growth company policy shionogi shionogis purpose shionogi strives constantly supply best possible medicine protect health wellbeing patient serve purpose shionogi need pursue search even better medicine produce even better medicine promote awareness better medicine people people able use medicine research produce promote even economical manner purpose shionogi people need strive ceaselessly day day improve skill strive ceaselessly day day improve human being result shionogi people find even greater satisfaction daily work daily life find even greater improvement quality life find even greater prosperity life established 1957 shionogis action guideline mission vision value mission deliver pharmaceutical offer even higher level satisfaction patient family healthcare provider improve quality life patient family vision company strong presence worldwide company pride dream embrace challenge value customer focus trust professionalism onsite orientation respect individual content management 02 management 02 shionogis 135year history 04 stakeholder 06 snapshot 08 performance highlight 10 interview president shionogis business 20 shionogis business activity activity 20 research 22 development 24 sale 25 overseas business activity 28 manufacturing editorial policy 30 pipeline period review 32 major product fiscal 2012 april 1 2012march 31 2013 certain activity continuing fiscal 2012 also included scope organization shionogis csr 34 shionogis csr activity annual report encompasses activity shionogi co ltd activity 34 fundamental policy csr 38 company 32 consolidated subsidiary 6 affiliate section entitled effort preserve environment cover 35 community relation business facility shionogi co ltd six domestic subsidiar 37 relationship employee y report shionogi refers shionogi co ltd onsite subsidiary 38 effort preserve environment domestic subsidiary refers one domestic manufacturing subsidiary shionogi pharma chemical co ltd two domestic nonmanufacturing subsidiary shionogi general service co ltd saishin igaku co ltd shionogi group refers aforemen management 40 management system tioned company system 40 corporate governance note concerning numerical value graph 44 member board numerical value rounded nearest unit applicable total may match due rounding financial 46 financial section forwardlooking statement section 46 tenyear consolidated financial highlight report contains forwardlooking statement statement 48 management discussion analysis based expectation light information currently available assumption subject risk uncertainty could 51 business risk cause actual result differ materially statement risk uncertainty include general domestic international 52 consolidated financial statement economic condition general industry market condition change interest rate currency exchange rate risk uncertainty particularly apply forwardlooking corporate 74 corporate information statement concerning existing product development product risk uncertainty include limited comple information 74 shionogi group directory tion discontinuation clinical trial obtaining regulatory approval claim concern product safety efficacy technological 75 corporate information advance adverse outcome important litigation domestic foreign healthcare reform change law regulation existing product also manufacturing marketing risk include limited inability build production capacity meet demand unavailability raw material competi tion company product company disclaims intention obligation update revise forwardlooking statement whether result new information future event otherwise report contains information pharmaceutical including compound development information intended make representation advertisement regarding efficacy pharmaceutical provide medical advice kind shionogi annual report 2013 01 shionogis business activity shionogis csr activity management system financial section corporate information management shionogis 135year history shionogi positioned fiscal 2013 first year group globalization based tradition history stretching back 135 year company foundation shionogi looking realize company policyto strive constantly supply best possi ble medicine protect health wellbeing patient serveon global basis 1878 1900 1950 1878 1909 1957 gisaburo shiono sr founder corporate emblem fundoh company policy shionogi company launched shiono gisaburo registered established shoten drug wholesaler present site head office fundoh mean pursue 1963 taiwan shionogi co ltd doshomachi osaka truth established shionogis corporate emblem founder derived fundoh 1968 weight used measure established settsu plant gisaburo shiono sr medicine balance sym 18541931 bolizes accuracy honesty 1980 gisaburo shiono sr established developmental research trust express born 1854 doshomachi laboratory shionogi pharmaceutical shionogis wish constant osaka guidance research center sprc pursuit truth father kichibe learned wholesale trade 1983 march 17 1878 fundoh edo era constructed kanegasaki plant launched drug wholesaling business 1997 doshomachi 24th 1909 launched cephem antibiotic flomox antacidin antacid agent launched birthday wholesaler predecessor first drug produced 1998 established shionogi charter shionogi co ltd 1910 conduct manufacturing plant shiono seiyakusho constructed 1886 13 management shionogi decided con 1919 centrate imported western drug shiono gisaburo shoten shiono seiyakusho merged new company named 1897 shionogi shoten co ltd shionogi started deal directly trading firm europe u 1922 established kuise plant kuise site 1943 company renamed shionogi seiyaku kk shionogi co ltd 1946 developed aburahi laboratory aburahi facility 02 shionogi annual report 2013 shionogi limited uk co pharmaceutical shionogi inc development foothold eu technology holding limited development manufacturing sale rd manufacturing sale pharmaceutical u pharmaceutical china 2000 2005 2010 2000 2005 2010 first mediumterm second mediumterm third mediumterm business plan start business plan start business plan start laying foundation accelerating toward significant stride song real growth completion corporate restructuring established constant flow pipeline product launch multiple product developed concentrate pharmaceutical business energizing globalizing rd globally real growth launched hyperlipidemia treatment crestor launched antiviral drug influenza 2001 launched carbapenem antibiotic finibax rapiacta established shionogi usa inc sold bushu pharmaceutical ltd contract shionogi inc 2007 manufacturing company transferred agricultural chemical business launched cancer pain analgesic oxinorm launched antidepressant drug cymbalta established joint venture named shionogi 2008 established pet molecular imaging glaxosmithkline pharmaceutical llc established shionogi analysis center co ltd center osaka university graduate shionogiviiv healthcare llc school medicine launched hypertension treatment irbetan started joint research development established shionogi inc u established joint research facility hok including hiv integrase inhibitor group headquarters kaido university shionogi innovation center 2002 drug discovery established shionogi techno advance transferred veterinary drug business acquired sciele pharma inc research co ltd clinical laboratory shionogi inc sold ohmori co ltd wholesaler 2011 launched acne vulgaris treatment differin completed new research facility sprc4 pharmaceutical launched idiopathic pulmonary fibrosis acquired chinese pharmaceutical 2003 treatment pirespa company co pharmaceutical 5th launched cancer pain analgesic oxycontin 2009 technology holding limited established ezose science inc venture com pany providing serum glycan analysis service 2012 established european subsidiary shionogi limited launched injectable cancer pain analgesic oxifast revised hiv integrase inhibitor relationship viiv 2013 launched postmenopausal vulvar vaginal atrophy treatment osphenatm shionogi annual report 2013 03 shionogis business activity shionogis csr activity management system financial section corporate information management stakeholder shionogi group pushing ahead third mediumterm business plan aim achieving growth medium long term shionogi group midst implementing third mediumterm business plan spanning period fiscal 2010 fiscal 2014 plan designed enable shionogi group overcome crestor cliff phrase refers expected drop royalty income resulting expiration patent hyperlipidemia treatment crestor mainstay product 2016 2017 continue grow royalty income thereafter working hard bring innovative new drug market globally expand earnings realize medium longterm vision fiscal 2014 management target fiscal 2020 aim consolidated net sale 3750 billion consolidated net sale 6000 billion operating income 1100 billion operating margin least 25 overseas net sale 870 billion overseas net sale ratio least 50 president ceo chairman board 04 shionogi annual report 2013 fiscal 2012 halfway point business plan year many accomplishment fiscal 2012 year ended march 31 2013 secured stable earnings japanese market absorbing impact nhi drug price revision steady growth eight strategic product particularly new drug overseas market stable operation produced improved profitability u subsidiary shionogi inc chinese subsidiary co1 made first fullyear contribution net sale thus making steady progress solidifying base shionogi group grow globally fiscal 2012 significant year term development compound underpin future growth antihiv drug october 2012 entered agreement substantially revised inte grase inhibitor relationship ukbased development partner viiv2 clarified future earnings prospect december 2012 viiv filed new drug application nda u eu canada anti hiv agent dolutegravir generic name expects gain approval launch drug u summer 2013 whats treatment postmenopausal vulvar vaginal atrophy osphenatm ospemifene gained regulatory approval u february 2013 launched following june compound latestage clinical development global basis also made steady progress earnings front part effort improve earnings structure ahead crestor cliff worked reduce cost even across company result effort income level higher level prior fiscal year working ensure achieve business plan target fiscal 2013 stepping globalization grow 2016 crestor cliff aim secure stable earnings japan mother market time continuously launch proprietary product subsidiary u world largest pharmaceutical market fastgrowing chinese market grow steadily global basis term research development addition priority therapeutic area metabolic syndrome take challenge research new therapeutic area high unmet medical need3 including central nervous system disorder determined quickly develop future growth driver globally also utilizing uk subsidiary shionogi group work one steadily execute basic strategy third mediumterm busi ness plan meet demand society develop continuously way realize company policy shionogi globally deliver tangible benefit growth stakeholder look ward receiving ongoing support guidance stakeholder 1 co pharmaceutical technology holding limited 2 viiv healthcare ltd 3 refers condition remains satisfactory method treatment shionogi annual report 2013 05 shionogis business activity shionogis csr activity management system financial section corporate information management snapshot shionogi medium longterm vision overcome socalled crestor cliff fiscal 2020 enter era renewed growth era renewed growth fiscal 2020 aim consolidated net sale 6000 billion domestic net sale operating margin overseas net sale least 25 fiscal 2014 crestor royalty plan overseas net sale ratio others net sale least 50 3750 billion fiscal 2013 forecast net sale 2870 crestor cliff expected drop royalty income resulting billion expiration fiscal 2012 patent crestor net sale leading product 2829 billion fiscal 2010 net sale 2824 billion global development nurture future growth driver compound s297995 s555739 cancer vaccine etc global hiv grow antihiv agent integrase inhibitor royalty income dividend viiv healthcare global new product grow new drug osphenatm overseas sale expansion domestic grow eight strategic product strategy solidify domestic marketing base 2010 2012 2013 2014 2016 2018 2020 three basic strategy third mediumterm steady growth mainly enriched pipeline fourth mediumterm business plan investment new growth driver business plan yet announced therapeutic area focused 06 shionogi annual report 2013 fiscal 2012 achievement global new drug treatment postmenopausal vulvar vaginal atrophy osphenatm ospemifene filed regulatory approval obtained regulatory please refer u april 2012 approval page 15 february 2013 filed regulatory approval launched june 2013 eu march 2013 global antihiv agent dolutegravir integrase inhibitor global antihiv substantially revised integrase inhibitor relationship agent market please refer viiv october 2012 approx page 13 us168 billion filed regulatory approval u canada eu fy2011 december 2012 source evaluate pharma 2011 global latestage clinical development product phase phase ii alleviation opioidinduced adverse effect s297995 9 12 compound compound please refer started phase iii clinical trial globally page 17 3031 allergic rhinitis treatment s555739 phase iii submission approval phase iii lpo seasonal allergy japan 9 4 last patient compound compound august 2013 eight strategic product japan net sale share sale billion yen fy2010 fy2011 fy2012 steadily expanding sale 37 45 51 please refer 583 732 842 page 3233 increased share 51 prescription drug sale japan prescription drug sale japan 1589 1644 1657 cost management operating income billion yen achieved record operating income fy2012 588 fy2011 470 fy2010 469 appropriately efficiently controlled expense shionogi annual report 2013 07 shionogis business activity shionogis csr activity management system financial section corporate information management performance highlight thousand million yen u dollars1 fy2008 fy2009 fy2010 fy2011 fy2012 fy2012 year ended march 31 net sale 227512 278503 282350 267275 282904 3009297 cost sale 70929 76264 81737 77753 78575 835815 selling general administrative expense 124568 149801 153721 142519 145480 1547495 operating income 32015 52438 46892 47003 58849 625987 income income tax minority interest 30786 58541 33135 41495 58307 620221 net income 15661 38626 20027 27102 66728 709797 research development expense 52822 51808 50921 53599 53021 563993 capital investment 10875 12547 17967 13233 11447 121764 depreciation amortization 13468 18048 17966 16282 11912 126710 net cash provided operating activity 29120 52902 56528 54724 59276 630529 net cash used investing activity 149056 826 13947 38290 19960 212318 march 31 property plant equipment net 71812 62448 70221 74282 78474 834741 total asset 501853 540762 523242 522162 574882 6115115 total longterm liability 114955 131956 115326 92900 53042 564216 total net asset 310094 341976 328096 347198 423633 4506255 per share amount yen u dollar net income 4675 11533 5980 8093 19925 212 net asset 92443 101971 97969 102783 125444 1334 dividend 2800 3600 4000 4000 4200 045 equity ratio 617 632 627 659 731 return equity roe 48 119 60 81 175 return asset roa 70 97 85 88 107 payout ratio 599 312 669 494 211 nonfinancial data co2 emission thousand ton co22 104 87 93 89 amount waste generated 5875 6218 5015 4744 4564 ratio hybrid electric vehicle 3 397 489 800 1 u dollar figure calculated convenience rate 9401 us100 approximate rate exchange march 31 2013 2 electric power co2 conversion us internally specified figure data fiscal 2009 change scope aggregation following enforcement amended act temporary measure promotion rational us energy recycled resource 2010 3 excludes cold region japan 08 shionogi annual report 2013 net sale overseas net sale ratio operating income net income net income ratio operating income ratio billion yen billion yen billion yen 4000 400 600 588 billion 300 800 400 point 3 345 667 billion point 1 3000 300 600 300 2829 billion 208 400 200 236 2000 200 400 200 200 100 1000 100 200 point 2 100 0 0 0 0 0 0 2008 2009 2010 2011 2012 fy 2008 2009 2010 2011 2012 fy 2008 2009 2010 2011 2012 fy net sale operating income net income overseas net sale ratio operating income ratio net income ratio research development expense roe roa dividend per share payout ratio research development expense ratio billion yen yen 600 300 200 60 800 530 billion 175 150 45 600 42 yen 400 187 200 107 100 30 400 200 100 50 15 200 211 0 0 0 0 0 2008 2009 2010 2011 2012 fy 2008 2009 2010 2011 2012 fy 2008 2009 2010 2011 2012 fy research development expense roe dividend per share research development expense ratio roa payout ratio point 1 reflects sluggish performance u business point 2 reflects extraordinary loss including loss disaster attributable great east japan earthquake business structure improvement expense impairment loss u operation point 3 reflects lower tax expense due impairment loss valuation stock affiliate nonconsolidated basis associated revaluation u operation stock data yen 2500 2000 1500 1000 500 2008 2009 2010 2011 2012 2013 4 7 10 1 4 7 10 1 4 7 10 1 4 7 10 1 4 7 10 1 3 shionogi annual report 2013 09 shionogis business activity shionogis csr activity management system financial section corporate information management interview president president ceo isao teshirogi phd 10 shionogi annual report 2013 shionogi positioned fiscal 2013 first year group globalization work course year toward realizing company policy globally wake realignment within domestic pharmaceutical industry consequence widespread activityand multinational drugmakers pushing deeper japanese market shionogi group established development sale base u europe asia view ensuring ongoing steady independent growth rdoriented global pharmaceutical company result effort poised move onto higher growth trajectory fiscal 2013 group whole clarify priority determining cost allocation putting highest priority new product launched u market mean growing overseas sale identified fiscal 2013 first year shionogis globalization also seek plant domestic employee realization shionogi global company requiring adopt much broader mindset continuous global development breakthrough new drug required shionogi group survive fierce competition overcome crestor cliff occur 2016 2017 achieve growth postcrestor era end employee working one realize shionogi company policy globally spirit striving con stantly ensure patient around world access best new drug soon humanly possible shionogi annual report 2013 11 shionogis business activity shionogis csr activity management system financial section corporate information management interview president question first could outline initiative taken globalize 1 operation mean overcoming crestor cliff describe result seen fiscal 2012 domestic prescription pharmaceutical market expected expand going ward shionogi must pursue significant presence large u european market well china emerging economy expected experience high growth ever must apply global perspective determining best utilize group limited resource term manpower good capital order maximize value pipeline product bringing market quickly essential make timely decision product prioritize market whether best case go alone develop product jointly another company alternatively secure licensing agree ment sense fiscal 2012 important year term laying groundwork globalization shionogi group revised agreement viiv healthcare 1 concerning antihiv drug believe evolve key pillar earnings october 2012 restructured agreement ukbased pharmaceutical company viiv healthcare partner joint development antihiv drug hope become important source income shionogi group revision concern sale right management operation amended agreement continue say management 10 shareholder viiv addition receiving royalty fixed percentage sale dividend viiv believe change allow u dedicate resource development sale proprietary global product antihiv agent dolutegravir granted priority review status fda expect approval launch take place summer 2013 fda u food drug administration 12 shionogi annual report 2013 strategy surmounting crestor cliff 1 relationship viiv concerning antihiv drug n right dolutegravir hiv integrase inhibitor1 franchise product shionogi transferred viiv shionogi becoming 10 shareholder viiv gsk pfizer co ltd japan n receive dividend viiv proportionate 10 shareholding 100 also entitled representation viivs board one person n receive royalty averaging high teen sale dolutegravir shionogi ltd franchise product uk shareholding principle amout decline even combination preparation 765 135 10 merit new framework viiv group representation viivs board shionogi say management uk make ongoing contribution maximizing value dolute gravir franchise product thereby augmenting royalty income jv2 resource previously used integrase inhibitor development chan neled rd internally developed product achieve early global launch growth driver succeed dolutegravir antihiv drug market hiv infected people approx 34 million source unicef unaids progressive report 20113 antihiv market approx us168 billion source evaluatepharma 2011 10 yearonyear increase regional breakdown u approx 47 country approx 53 profile dolutegravir dolutegravir nextgeneration hiv integrase inhibitor jointly developed shionogi viiv discovered joint research shionogi glaxosmithkline plc n viiv filed ndas u europe canada december 17 2012 n fda granted priority review designation n product profile high degree clinical activity phase iii trial conducted treatmentnaive patient approximately 90 patient dolutegravir group maintained viral load less 50 copy per ml 48week data unlikely produce drugresistant virus treatmentnaive patient observation dolutegravir producing virus resistant either dolutegra vir drug used combination background therapy low crossresistance also effective patient failed therapy using existing integrase inhibitor good pharmacokinetics taken daily without need pharmacokinetic booster4 administered together antihiv drug without need dose adjustment 1 integrase inhibitor block hiv replication inside body preventing viral dna integrating genetic material human immune cell 2 jv previous agreement shionogi held 50 right 3 global hiv aid response report issued world health organization united nation childrens fund unicef joint united nation programme hiv aid unaids 4 used combination maintain improve drug antiviral effect maintaining sufficient drug concentration blood drugmetabolizing enzyme inhibition shionogi annual report 2013 13 shionogis business activity shionogis csr activity management system financial section corporate information management interview president 2 launched osphenatm u shionogi group first global drug june 2013 saw launch u world largest pharmaceutical market shionogi group first global drug osphenatm treatment postmenopausal vulvar vaginal atro phy vva right entire group top priority quickly maximize value osphenatm believe significant role play improving patient qol quality life fiscal 2013 group strive one increase sale osphenatm u market march 2013 also submitted marketing authorization application maa european medicine agency ema process selecting commercialization partner eu hope also quickly deliver drug patient suffering vva europe well contribute treatment believe aforementioned change agreement viiv regarding antihiv drug u launch global product osphenatm development paved way shionogi overcome crestor cliff grow operation also working enrich accelerate development pipeline secure growth driver two product eye enhancing development efficiency shionogi strengthen global portfolio management redoubling effort develop market proprietary medicine across entire networkin japan u europe also china osphenatm launched june 2013 14 shionogi annual report 2013 strategy surmounting crestor cliff 2 global drug osphenatm osphenatm provides new treatment option many woman troubled dyspareunia painful intercourse due menopause approximately 32 million postmenopausal woman u experience symptom vva around 23 million treated prescription medication seems majority woman vva treated woman doctor proactively discussing condition symptom postmenopausal vulvar vaginal atrophy vva market 2012 u woman population 157 million x41 postmenopausal 45 year 64 million x50 population woman vva 32 million x30 unmet medical need estimate 60 vvadiagnosed patient 96 million woman arent treated x24 prescription drug patient treated prescription drug 23 million n product profile osphenatm estrogen agonist antagonist tissue selective effect first oral alternative existing vaginal estrogen bind estrogen receptor resulting activation estro genic pathway tissue agonism blockade estrogenic pathway others antagonism clinical trial confirmed efficacy safety osphenatm demonstrated significant improvement dyspareunia relative placebo form increase propor tion superficial cell decrease proportion parabasal cell reduction vaginal ph n schedule eu submitted maa march 2013 asia consideration shionogi annual report 2013 15 shionogis business activity shionogis csr activity management system financial section corporate information management interview president question please discus global development compound 2 believe function new growth driver alongside dolutegravir osphenatm pipeline includes number product believe hold key shionogis future growth among cancer peptide vaccine latestage development compound s297995 alleviation constipation opioidinduced adverse effect allergic rhinitis treatment s555739 furthermore october 2012 expanded offering one core therapeutic area entering license agreement kotobuki pharmaceutical co ltd hypercholesterolemia treatment different mechanism action crestor month inked agreement usbased janssen pharmaceutical inc aimed speeding development maximizing value drug candidate sphere alzheimers disease treatment thereby enhancing contribution patient worldwide term contract drug candidate alzheimers disease discovered shionogi employing new mechanism action licensed janssen wealth experi ence expertise development therapeatic area rd promotion collaboration japanese international university research institution contributed already discovery innovative new drug candidate also significant think vva treatment osphenatm secured fda approval schedule favorable condition era new drug obstetrics gynecology fre quently knocked back source pride regard testament shionogi group improved development prowess shionogi continue striving bring revolution ary new product patient around world soon humanly possible maintaining cre dentials rdoriented global pharmaceutical company keeping rd expenditure around 20 consolidated sale clearly defining priority assigned individual compound prescription narcotic 16 shionogi annual report 2013 treatment alleviating opioidinduced adverse effect s297995 generic name naldemedine n feature oral medication minimal cns effect selectively target peripheral opioid recep tor therefore effectively alleviating opioidinduced adverse effect including constipation nausea vomiting exerting adverse impact analgesic effect opioids n result clinical trial date verified relief opioidinduced constipation oic evidence central opioid withdrawal change pain intensity opioid dosage oncedaily administration generally well tolerated favorable pharmacokinetics low interindividual variability dosedependent exposure n development stage global conducted end phase ii meeting fda started phase iii clinical trial japan preparing start phase iii clinical trial allergic rhinitis treatment s555739 n feature combination therapy antihistamine show remarkable suppressive effect vari ous symptom allergic rhinitis surpassing existing oral antiallergy agent demonstrated possibility replacing steroid nasal spray new oral treatment n result clinical trial date among dp1 receptor antagonist first world demonstrate clinical efficacy allergic rhinitis effective given daily demonstrated good tolerance safety n development stage japan conducting phase iii clinical trial seasonal allergic rhinitis started phase iii clinical trial perennial allergic rhinitis europe completed pom proof mechanism study u conducted phase iia clinical trial one prostaglandin d2 receptor shionogi annual report 2013 17 shionogis business activity shionogis csr activity management system financial section corporate information management interview president question please describe current state future outlook 3 chinese business china pharmaceutical market track overtake japan second largest world co pharmaceutical technology holding limited co subsidiary since 2011 shionogi group used many year experience promoting proper use drug infectious disease japan garner greater share chinese market principally antibiotic unfortunately however shionogis drug still sufficiently reached chinese patient aim steadily grow shionogi group china sale medium long term process make greater contribution medical care china achieved co develop launch new shionogibrand product also promote research development collaboration chinese academic center excellence largely beijing shionogi phar maceutical technology limited another china subsidiary launched june 2013 overview beijing shionogi pharmaceutical technology limited company name beijing shionogi pharmaceutical technology limited representative masaaki takeyasu head office room 2443 level 24 tower 3 china central place 77 jianguo road chaoyang district beijing 100025 date establishment march 29 2013 capital 30 million business description technical support clinical development sale marketing information consulting question intention restructuring group production 4 supply chain organization april 2013 undertook organizational change aimed improving accuracy global production setup supply chain management scm work ensure stable supply highquality product globally promoting greater collaboration manufacturing divi sion newly created global scm division optimizing operation reducing cost sale global manufacturing management system spanning production strategy planning procurement manufacturing inventory control new approach scm got first test june 2013 u launch new vva treatment osphenatm 18 shionogi annual report 2013 question finally please discus initiative planned increase corporate value 5 shareholder return medium long term shionogi group basic policy profit distribution maintain stable dividend share holder taking account capital demand future business development profit earned relevant fiscal period among company major achievement fiscal 2012 revision alliance viiv concerning development antihiv drug believe new scheme clarifies future earnings prospect dolutegravirwhich expect attain blockbuster statusand franchise product believe u launch osphenatm treatment vva succeeded stabilizing longerterm outlook overseas operation enhancing prospect growth event end fiscal 2012 shionogi increased consolidated dividend payout ratio target 35 40 return profit shareholder based new dividend policy shionogi raise yearend cash dividend fiscal 2012 2 per share 22 together interim cash dividend therefore pay annual cash dividend 42 per share shionogi group continue proactively undertake business activity eye enhancing corporate value longerterm objective steadily increase return deliv ered shareholder dividend per share payout ratio yen 60 800 dividend per share payout ratio 45 44 yen 600 42 yen 30 398 400 15 200 211 0 0 2008 2009 2010 2011 2012 2013 fy forecast dividend policy shionogi aim raise dividend steadily line performance consolidated dividend payout ratio target 40 consolidated payout ratio approx 40 based net income excluding onetime positive effect tax expense shionogi annual report 2013 19 management shionogis business shionogis csr activity management system financial section corporate information activity research fiscal 2012 achievement fiscal 2013 target saving patient worldwide proprietary innovative new drug fiscal 2012 shionogi reached final step supply patient worldwide anti hiv agent dolutegravir drug created jointly uk glaxosmithkline plc phase iii clinical trial proven significantly effective existing treatment also advanced proprietary drug s555739 proprietary drug candidate allergic rhinitis s297995 proprietary drug candidate alleviating opioidinduced adverse effect latestage clinical trial nearing goal helping patient around world groundbreaking new drug developed internally furthermore number alzheimers disease patient increasing background aging corporate officer senior vice president society shionogi also licensed drug candidate belonging class known bace pharmaceutical research division inhibitors2 janssen pharmaceutical inc u time also entered kohji hanasaki phd research collaboration discovery backup compound delivering advance small molecule drug discoveryan area existing expertiseshionogi also expanding aggressively large molecule pharmaceutical area output third mediumterm business plan target drug candidate includes antipseudomonas aeruginosa antibody developed inhouse cancer peptide vaccine inlicensed oncotherapy science inc moreover shionogi focusing effort accelerating rd activity field oligonucleotide drugs3 including antisense decoy nucleic acid alliance following three area enhancement early phase researchportfolio new drug creation hinge innovation improvement predictive perfor shionogis third mediumterm business plan pharmaceutical research division mance clinical efficacy cen committed searching groundbreaking drug discovery seed improving predic tralization function tive performance clinical efficacy search drug discovery seed shion strengthening flexibility ogi early adopter domestically overseas open innovation industry set two numerical performance academia uncover academic research seed matching company research need thus far collaboration included find ssp flash4 target first select four strengthen effort identify mature novel seed joint research new molecular entity nmes industry academia fiscal 2012 expanded ssp program include australia drug candidate selection per year belgium denmark luxembourg netherlands addition uk second create nmes bid improve predictive performance clinical efficacy continue success rate 50 engage research molecular imaging technology pet molecular imaging poc1 study center osaka university graduate school medicine using internally devel oped pet imaging probe confirmed nonclinical efficacy central nervous system cns compound development preparing framework manufacture pet imaging formulation gmp5 well entering prepara tions microdosing clinical study collaboration osaka university hospital collaborative research ip cell undertaken shionogi innovation center ground hokkaido university stage utilizing ip cell research cns disease assay method would correlate clinical event march 2013 entered comprehensive collaboration agreement medical innovation center kyoto university graduate school medicine agreement kyoto university shionogi collaborate create innovative medicine treatment alzheimers disease cns disorder seeking meet critical unmet medical need basic research regarding underlying pathology thereby finding new drug target regeneration synapsis neuronal function collab oration also promote training development academic industrial scien tists medicine drug discovery research 20 shionogi annual report 2013 voice frontline help realize goal outlined shionogis third mediumterm business plan pharmaceutical research division also using shionogi pharmaceutical research center engage collaborative research shionogi techno advance research co ltd star shanghai sunsail pharmaceutical science technology co ltd research subsidiary chinese company co pharmaceutical technology holding lim ited remaining active researchdriven pharmaceutical company strive con stantly improve science productivity relationship creativity better realize company policy global perspective creating providing new medicine medicinal research laboratory eagerly awaited patient shionogi family worldwide takashi kawasuji 1 poc study human clinical trial designed demonstrate early sign product efficacy proof concept shionogis antihiv drug research team 2 drug block activity betasecretase enzyme needed generation betaamyloid protein comprises member varying specialty substance identified causing alzheimers disease 3 drug composed nucleotide dna rna act directly gene protein known cause disease working one pursue drug discovery 4 find domestic drug discovery competition pharmainnovation discovery competition shionogi research pursuit company ssp overseas drug discovery competition shionogi science program flash drug discovery initiative osaka university graduate school medicine pharmalink goal year tire academia shionogi less search better compound 5 standard quality control production management quasidrugs pharmaceutical product good often verge collapse variously manufacturing practice employing cuttingedge science wealth creativity firm resolve upshot work dolutegravir many people worked feverishly development drug intellectual property 2013 start supply shionogi group global intellectual property strategy forged close link ing patient pleasure rd strategy business strategy also provides support alliance able real thrill drug activity patent protection marketed pipeline product discovery research case research development company work reserve suitable patent prime motivation right development compound substance drug discovery target basic research technology also maximizing patent protection period protect ing patent revenue efficiently obtaining patent regarding indication crystalline form manufacturing method formulation activity shionogi filed approximately 110 patent application fiscal 2012 40 filed overseas eye growth emerging market company stepped patent filing country company periodically review patent portfolio taking cost account march 31 2013 shionogi held approximately 190 patent japan 120 patent family overseas part business strategy company take every care conduct intel lectual property due diligence inlicensing outlicensing product ward potential patent infringement shionogi also engaged brand design activity mean reliability assurance company product combating counterfeiting fiscal 2012 company filed 31 application trademark registration 13 application design registration evolution pharmaceutical manufacturer shionogi continue working one implement intellectual creation cyclewhich creates pro tects generates earnings intellectual property shionogi annual report 2013 21 management shionogis business shionogis csr activity management system financial section corporate information activity development fiscal 2012 achievement fiscal 2013 target two major achievement fiscal 2012 saw shionogi chalk two major achievement one obtaining regula tory approval first new chemical entity filed shionogi u filing new drug application u europe canada april 2012 shionogi filed new drug application u selective estro gen receptor modulator osphenatm generic name ospemifene regulatory approval received scheduled february 2013 furthermore shionogi filed regulatory approval europe march 2013 shionogi developing antihiv agent dolutegravir jointly viiv senior executive officer senior vice president global development healthcare ltd october 2012 shionogi acquired share viiv revised royalty pharmaceutical development division agreement time transferred development right viiv december takuko sawada 2012 new drug application submitted u food drug administration fda european medicine agency ema canada planned third mediumterm business plan mission accelerating global development two latestage drug currently two global product latestage clinical development s297995 shionogi endeavoring enhance alleviation opioidinduced adverse effect s555739 treatment development function worldwide allergic rhinitis started phase iii clinical study globally s297995 based result end phase ii meeting held february 2013 fda time unify s555739 clinical trial conducted japan u europe global clinical development strategy japan highest unmet medical need regard hay fever treatment phase specific target third iii trial conducted advance country going forward aim mediumterm business plan accelerate global development prioritizing resource two product make submission overseas regulatory approval four com maximizing rich pipeline pound originating shionogi also japan promoting multiple latestage development including throm bocytopenia treatment attention deficit hyperactivity disorder adhd drug japanese research institute well duloxetine additional indication fibromyalgia chronic low back launch one product pain oxycodone additional indication noncancer pain globally develop taking phase iii clinical trial several compound developed domestically five latestage product shionogi overseas aim quickly supply drug outside latestage development program also working next global market generation therapy form cancer peptide vaccine antibody drug looking ahead shionogi seek identify select development compound even earlier stage prioritizing rd expense compound also exploring partnership outlicensing inlicensing opportunity view getting wealth development asset see page 30 pipeline list compound 22 shionogi annual report 2013 voice frontline target milestone fy2013 global development compound name indication progress target alleviation opioid s297995 global phase iii initiation induced adverse effect s555739 allergic rhinitis u eu phase ii completion s5884101 bladder cancer eu poc initiation s222611 malignant tumor eu phase ii initiation s649266 bacterial infection u phase ii initiation s120083 inflammatory pain u phase ii initiation global development office s117957 neuropathic pain u pom2 initiation tamio fujiwara target milestone fy2013 domestic development pharmaceutical development involves compound name indication progress target cymbalta chronic low back pain phase iii initiation teamwork great pleasure alleviation opioid utilize team member opinion formu s297995 phase iii initiation induced adverse effect lating development strategy s555739 allergic rhinitis phase iii codebreak seasonal allergic rhinitis creating protocol report academic s888711 thrombocytopenia phase iib codebreak go nogo decision presentation based individual clinical s2367 obesity phase iib codebreak go nogo decision s556971 dyslipidemia phase iib codebreak go nogo decision nonclinical trial ultimately allergic rhinitis caused creates highquality package illus s524101 phase ii iii codebreak housedust mite allergen trates compound characteristic agerelated macular best possible light whole phar s646240 phase iia codebreak go nogo decision degeneration s5884101 bladder cancer poc initiation maceutical development full chal s120083 inflammatory pain phase ii initiation lenges regarding clinical science 1 fivepeptide cocktail vaccine requires scientific logical thinking 2 proof mechanism data thus generated keep stim ulated excitement anticipation day another shion shionogi limited ogi baby come world uk subsidiary shionogi limited established february 2012 promote pharmaceutical devel opment industryacademic collaboration europe well follow hta establishment acceptance trend worldwide aim incor porating finding development plan march 2013 shionogi limited submitted market ing authorisation application maa ospemifene via combination inhouse sale ceo partnering subsidiary working toward achieving development sale objective takashi takenoshita mediumterm business plan eu shionogi science program initiated uk fiscal 2011 col laborative industryacademia initiative expanded scope include country promoting collaboration european academia joint effort shionogis pharmaceutical research division innova tion design office health technology assessment shionogi annual report 2013 23 management shionogis business shionogis csr activity management system financial section corporate information activity sale fiscal 2012 achievement fiscal 2013 target expanded market share 8 strategic product making progress drive create earnings structure dependent longlisted drug domestic sale shionogi focusing expanding sale 8 strategic product executes one basic strategy third mediumterm business plan namely steady growth mainly enriched pipeline fiscal 2012 shionogi launched aimix irbetan family product oxifast oxycontin family product well added indication cymbalta fini executive officer bax thereby raising shionogis presence priority market cardiovascular senior vice president metabolic disorder pain infectious disease human health care division result fiscal 2012 sale crestor rose 7 year year 381 billion sale ryuichi kume phd irbetan family product climbed 20 107 billion sale cymbalta leapt 47 97 billion lifted sale 8 strategic product 15 year year 842 billion third mediumterm business plan mission steadily executing basic strategy new organization fiscal 2014 aim achieve anticipate change business climate including hike consumption net sale japan 200 billion tax rate measure promote increased uptake generic drug revision increase combined sale japan healthcare system elderly order better deal change still implementing basic strategy third mediumterm business plan 8 strategic product least undertaken organizational reform following carried 2012 70 total domestic sale begin simplified organizational structure create wellbalanced mar keting mix 4cs customer value customer cost convenience communication view removing barrier top management frontline employee sought create even flatter organizational structure also improved educa tion training support medical representative mr order provide medical professional even betterquality product information fiscal 2013 shionogi augmenting lineup treatment cardiovascu lar metabolic disorder launch metreleptin well launch irbetan 200mg soontobelaunched irtra irbetan family drug line first basic strategy view achieving mediumterm objective pursue sale activity particular focus new product voice conversation healthcare professional endeavor listen attentively description patient concern learned individual see frontline patient disease attentiveness affords u thorough understanding various difficulty besetting patient healthcare professional enabling u offer customer solution built around shionogi product recently oncologist told patient suffering skin complaint due adverse reaction cancer treatment suggested therapy shionogi product grateful behalf company mr glad service patient continue giving pharmaceutical promotion department hope receiving word thanks many healthcare professional rie koyama 24 shionogi annual report 2013 overseas business activity fiscal 2012 achievement fiscal 2013 target u operation fiscal 2012 achieved performance target via raft reform aimed stabi lizing management shionogi inc strengthening operation developing highly profitable business structure effective utilization human resource received fda approval february 26 2013 launched osphenatm june 2013 treatment postmenopausal vulvar vaginal atrophy vva condition thought affect 32 million woman u among shionogi group global product osphenatm first win regulatory approval u took companywide effort looking ahead plan grow womens health new fran corporate officer senior vice president chise view expanding scope operation osphenatm differ overseas business division ent mechanism action traditional estrogenalone therapy task masaaki takeyasu fiscal 2013 utilize academic activity garner swift recognition among wom en health specialist drug efficacy safety also proactive undertaking directtoconsumer educational campaign encouraging woman broach third mediumterm business plan mission doctor sensitive subject painful intercourse due postmenopausal vva working create new market treatment also fit womens life overseas business division style contribute improved qol established january 2012 china taiwan operation mission delivering shionogi since 2011 china actively promoting responsible use antibiotic via new product huge potential administrative regulation governing clinical use antibacterial agent shionogi medical professional prior experience japan academic activity focused proper use antibiotic patient around world treating infectious disease provided co ample support respect end overseas business division bolster support academic activity june 2013 shionogi established soundly operating subsidiary local subsidiary beijing promote collaboration chinese academia globally absence new drug control infectious disease urgent issue u china taiwan well strive help many patient possible collaborating academic china exporting product taiwan asian nation promote rational use existing antibiotic deemed potential treating resistant bacteriaa scourge know border company policy shionogi espouses universal truth raison detre pharmaceutical company release osphenatm designated fiscal 2013 first year shionogis globalization company continue search unmet medical need europe asia elsewhere operating highquality business around world order fulfill social mission pharmaceutical manufacturer launch meeting osphenatm shionogi annual report 2013 25 management shionogis business shionogis csr activity management system financial section corporate information activity overseas business activity shionogi inc fiscal 2012 achievement fiscal 2013 target fiscal 2012 year significant progress shionogi inc achieved financial target realized six consecutive quarter ontarget financial perfor mance give u solid stable base build going forward initiative expanding osphenatm fiscal 2013 important event shionogi inc impending launch osphenatm firstin class oral drug treatment dyspareunia painful intercourse symptom vulvar vaginal atro shionogi inc phy vva due menopause approved fda february 26 2013 osphenatm represents first president ceo new chemical entity ever filed approved launched shionogi u 135year history john keller phd estimated 32 million woman u experiencing symptom vva 90 treated prescription medicine tremendous opportunity make difference patient establish innovative new entrant underserved area womens health osphenatms launch also represents turning point shionogi inc become major contributor shionogis global growth began fiscal 2013 therefore intensively preparing launch finalizing plan strengthening training sale force osphenatm also begun outreach womens health group expressed strong interest new therapy effort develop next proprietary drug osphenatm even given excitement osphenatm lost focus numerous clinical study initiating progressing u development shionogidiscovered pipeline perhaps important amongst initiation phase iii pivotal study naldemedine s297995 treatment opioidinduced constipation successful naldemedine succeed osphenatms first becoming first internally discovered new chemical entity launched shionogi u role corporate officer shionogi co ltd deeply honored named corporate officer shionogi co ltd 2013 reflec tion fully realize progress made u truly result dedicated team effort across global shionogi family whose member work intensively creatively advance pipeline support business together improve patient health quality life thus realize shionogis mission every day hope able contribute success shionogi co ltd globally within beyond shionogi inc voice work colleague successfully launch osphenatm u reflect back incredi ble collaboration global shionogi partner enabled shionogi inc reach mile frontline stone well nda filing clinical pharmacology reviewed accuracy pharmacokinetic data designed analyzed bioequivalence study one particular pivotal led nda filing nonclinical colleague ensured availability quality nonclinical senior director medical data required nda submission biostatistics group provided highquality timely review affairswomans health nda data package ran additional analysis support filing finally cmc worked shelli graham shionogi inc fully characterize osphenatm utilizing long history rd optimize production product group also played critical role responding question fda ultimately facilitated ontime approval osphenatm proud energized part team greatest hope collabo rative precedent set development osphenatm become model going forward maximizing global opportunity osphenatm pipeline product follow 26 shionogi annual report 2013 co mission co integrated pharmaceutical company engaged rd manufacturing distribution prescrip tion pharmaceutical product china 1100 employee across fastgrowing chinese market operate basic philosophy wishing long life creating brilliant future hand hand company mainstay product antibiotic spearheaded flumarin amolin amoxicillin china regulating use antibiotic co view change business climate opportunity growth conjunction parent company co continue provide customer appropri executive vice president ate information shionogi product view garnering greater market share also working masaki tomiyama toward early release doripenem time focus rd geared toward launch product discovered internally striv ing bring forward day roll first product originated co thereby improving life still patient realize shionogi company policy chinanamely striving constantly supply best possible medicine protect health wellbeing patient serveco redouble effort develop proprietary new drug also pursuing collaboration shionogi group company voice although co joined shionogi family 2011 employee secure belief helping advance company policy shionogi wealth experience frontline rdoriented pharmaceutical company many year standing member shionogi family co course committed upholding shionogi company policy striving constantly supply best possible medicine protect health wellbe executive vice president ing patient serve concomitantly aim build greater presence china enormous pharmaceutical market xu yan taiwan shionogi co ltds mission taiwan shionogi approaching 50th anniversary 2014 manner shionogi company pledged supply best possible medicine improve health wellbeing patient taiwan cur rently taiwan shionogi around 50 mr providing information company product special focus infectious disease company mainstay product antibiotic flumarin finibax flumarin currently ranking taiwan topselling injectable cephem antibiotic taiwan shionogi also preparing domestic launch rapiacta pirespa product already marketed japan field infec tious disease particular company remain actively engaged new drug development inlicensing president ceo taiwan shionogis marketing sale team rival parent term nationwide coverage com masami morita pany primary mission improve health patient taiwan beyond aim contrib ute shionogis business expansion asia bolstering human resource development building effective organization also entering partnership pharmaceutical company voice shionogis company policy built upon focus customer believe concept principle profit one universally accepted taiwan shionogi longest frontline history overseas base within shionogi group fully understands executes shionogi corporate philosophy take pride belief taiwan shionogis marketing sale team surpasses company capacity disseminate information general manager together local staff approach job every day conviction shionogi accounting department acting interest taiwanese patient relish able kenji kuroda shionogi annual report 2013 27 management shionogis business shionogis csr activity management system financial section corporate information activity manufacturing third mediumterm business plan mission shionogi implementing global quality assurance system basic goal strengthening production system ensuring stable supply support global launch inhouse product way shionogi harness ing strength ensure quality safety reliability shionogi brand mission collaboration organization new structure shionogis new division redoubling collaborative effort related organization also working ensure stable supply support timely global launch newly developed product improvement quality manufacturing division mission strengthen company quality maximizing manufacturing division primary mission ensure cash flow across group achieve create strong stable supply highquality product low cost prod partnership division involved flow supplier uct safety quality foremost priority customer manage entire supply chain efficiently course also committed ensuring safety health new organizational structure working employee reducing company environmental collaboration shionogi family around world footprint advance company global drive build ensure safe reliable delivery osphenatm doribax ing production network enable u supply shionogi future global product patient around world group product worldwide putting place necessary foundation tangible intangible comply quality safety regulatory affair global gmp management division quality safety regulatory affair management divi cmc development laboratory sionhaving responsibility supplying pharmaceutical prod april 2013 cmc development laboratory became ucts reliable efficacy safety qualityhas central role independent organization within company enhance play enhancing reputation shionogi brand productivity across entire research development spec achieved complying shionogi product trum even greater cooperation pharmaceutical policy conforming strictly pharmaceutical affair research division pharmaceutical development division law regulation governing process rd intensive cmc1 research aimed improving devel launch gxp2 thereby ensuring patient around opment success rate broad range stage extending world use shionogi product peace mind drug research development market launch give full pharmaceutical product impact directly human life play cmc technology active pharmaceutical ingredi always pay meticulous attention risk management work ents api manufacturing formulation etc ability ing ensure strict quality control activity involving create viable product thus transform drug discovery seed shionogi productsnot manufacturing also raw mate global pharmaceutical product provide even higher rial procurement forth accordance strict level satisfaction patient law regulation europe u also comply fully inspection regulatory authority employing global scm division pharmaceutical quality management system build maintain shionogi identified 2013 first year improve capacity efficiently consistently supply company globalization line established topcaliber product global scm gscm division april 2013 gscm divi 1 cmc refers chemistry manufacturing control sion purview cover group entire product range 2 gxp general abbreviation good practice standardsnamely glp good charge controlling manufacture laboratory practice gmp good manufacturing practice gcp good clinical time much quantity quality practice gvp good pharmacovigilance practice supplying product market timely fashion 28 shionogi annual report 2013 senior vice president message manufacturing division motto sqdce safety quality delivery cost environ ment based sqdce motto manufacturing division dedicated fostering fur ther advance production technology pursuing cost reform area considered offlimit ensure goal third mediumterm business plan met unwavering resolve upholding company policy intend strengthen cooperation division executive officer senior vice president manufacturing division takuo fukuda creation new drug demand overall competence research development cmc manufacturing role cmc development laboratory apply cmc technology chemistry manufacturing control compound deemed commercial poten tial reinvent pharmaceutical product suitable ingestion patient mission promote cmc souyaku cmcdirected innovative drug design devel opment approach enhance success rate new product launch combining pa sion younger researcher experience wisdom veteran form team professional pharmaceutical manufacturing corporate officer senior vice president cmc development laboratory kiyoshi nagata phd global scm division approach business three main goal 1 strengthen company scm capability develop worldwide 2 devise execute global production strategy 3 cultivate human resource able accomplish order achieve goal set three policy establishment aggressive gscm system operational innovation ii firm cost control toward cash flow maximization iii maximization capacity event control individual change proceed business collaboration related division corporate officer senior vice president global scm division hirosato kondo phd quality safety regulatory affair management division set three main goal achieved third mediumterm business plan 1 build imple ment global quality assurance system 2 upgrade predictive preventive risk manage ment 3 focus developing people achieve 1 2 fiscal 2013 shionogi positioned first year group globalization extremely important u handle issue regarding postmarketing osphenatm properly maxi mization value act achievement goal make division much proactive active effective management development human resource corporate officer senior vice president quality safety regulatory affair management division takayuki yoshioka phd shionogi annual report 2013 29 management shionogis business shionogis csr activity management system financial section corporate information activity pipeline shionogi three priority therapeutic area infectious disease metabolic syndrome pain company also focusing frontier field allergy cancer area code generic name product name category administration indication infectious disease s649266 cephem antibiotic injection infection angiotensin receptor antagonist s474474 irbesartan trichlormethiazide combination diuretic combination oral hypertension metabolic s556971 cholesterol absorption inhibitor oral dyslipidemia syndrome s707106 insulin sensitizer oral type 2 diabetes s234462 neuropeptide y5 receptor antagonist oral obesity duloxetine hydrochloride cymbalta serotonin noradrenaline reuptake inhibitor oral fibromyalgia ly248686 duloxetine hydrochloride cymbalta serotonin noradrenaline reuptake inhibitor oral chronic low back pain treatment moderate severe oxycodone hydrochloride hydrate oxycontin natural opium alkaloid oral chronic pain pain s297995 naldemedine peripheral opioid receptor antagonist oral alleviation opioidinduced adverse effect s117957 analgesic agent neuropathic pain oral neuropathic pain s120083 analgesic agent inflammatory pain oral inflammatory pain s288310 bladder cancer peptide s488410 cancer peptide vaccine injection esophageal cancer vaccine s488210 head neck squamous cell carcinoma s646240 peptide vaccine injection agerelated macular degeneration ospemifene selective estrogen receptor modulator oral postmenopausal vaginal atrophy eutectic mixture anesthetic metereddose topical psd502 lidocaine prilocaine aerosol spray premature ejaculation s555739 prostaglandin d2 receptor antagonist oral allergic rhinitis sublingual tablet housedust mite allergen extract allergic rhinitis caused housedust frontier s524101 immunotherapy mite allergen s877503 guanfacine hydrochloride alpha2aadrenergic receptor agonist oral attention deficit hyperactivity disorder s877489 lisdexamfetamine da ne reuptake inhibitor releaser da ne oral attention deficit hyperactivity disorder s888711 lusutrombopag small molecule tpo mimetic oral thrombocytopenia s222611 her2 egfr dual inhibitor oral malignant tumor s414114 nfkb decoy oligodeoxynucleotide topical atopic dermatitis gsk1349572 dolutegravir integrase inhibitor oral hiv infection outlicensing gsk1265744 lap integrase inhibitor injection hiv infection activity s0373 nonpeptide mimetic trh oral spinocerebellar ataxia janssen shionogi bace inhibitor bace inhibitor oral alzheimers disease long acting parenteral formulation 30 shionogi annual report 2013 august 2013 stage territory submission origin development phase phase iia phase iib phase iii approval japan shionogi glaxosmithkline inhouse uk u irbesartan sanofi france japan trichlormethiazide shionogi inhouse approval june 2013 shionogi kotobuki japan kotobuki pharmaceutical co ltd japan pharmaceutical co ltd u inhouse inhouse u japan eli lilly company u shionogi eli lilly japan kk japan japan napp pharmaceutical limited uk global inhouse inhouse japan preparation u pom proof mechanism shionogi purdue pharma shionogi purdue pharma lp u lp japan asia japan oncotherapy science inc japan inhouse europe japan u approval february 2013 shionogi quatrx pharma quatrx pharmaceutical company u ceuticals company europe nda submission march 2013 shionogi plethora solu u plethora solution holding plc uk tions holding plc japan u inhouse inhouse europe pom proof mechanism japan stallergenes sa france japan shire ireland shionogi shire japan japan preparation u europe inhouse inhouse europe japan anges mg inc japan shionogi anges mg inc global nda submission december 2012 shionogiviiv healthcare llc viiv healthcare ltd uk u kissei pharmaceutical co japan ltd japan inhouse janssen pharmaceutical europe inc u shionogi annual report 2013 31 management shionogis business shionogis csr activity management system financial section corporate information activity major product prescription drug 8 strategic product shionogi work steadily expand share japanese market focusing 8 strategic product crestor tablet irbetan tablet aimix combination tablet cymbalta capsule hyperlipidemia treatment irtra combination tablet irbetan family drug treatment depression depres launched april 2005 antihypertensive sive condition diabetic neuro irbetan tablet launched june 2008 aimix combination tablet launched pathic pain december 2012 irtra combination tablet preparation launch launched april 2010 shionogideveloped product statin therapy crestor longacting angiotensin ii receptor blocker arb strong 24hourlasting cymbalta serotonin noradrenaline proven highly effective lowering ldl hypotensive effect antimetabolic organprotecting effect following reuptake inhibitor approved antide cholesterol leader among dyslipid launch 2012 aimix combination tablet combining calcium pressant 100 country emia treatment japan overseas antagonist amlodipine shionogi making preparation launch recommended firstline treatment reduces risk atherosclerotic irtra combination tablet combining diuretic trichlormethiazide diabetic neuropathic pain dnp disease affords physician patient domestic international guideline greater sense satisfaction reliance sale billion yen fiscal 2013 424 120 115 620 forecast crestor tablet fiscal 2012 381 107 97 630 irbetan family fiscal 2011 357 89 66 647 cymbalta capsule crestor royalty income fiscal 2010 290 73 27 642 overthecounter otc drug overthecounter otc drug business shionogi working improve people quality life qol offering range otc drug product tailored individual lifestyle popon series sedes line line multiple vitamin mineral providing nutri line analgesic antipyretic chosen according pain tive support healthy life following initial launch prescription drug 1939 analgesic antipyretic sedes made popon brand long established history providing debut otc drug 1950 shionogi offer lineup sedes product tailored comprehensive nutritional support people need recently customer pain usage need among product sedes hi containing isopropylan stepped extended popon lineup includes popons tipyrine acetaminophen sedes hi demonstrates strong analgesic effect acute pain longselling multiple vitamin mineral originally launched no1 drug class based repeat use ratio product include sedes popon tablet marked 61st anniversary 2013 popons hi g granule sedes first recommended firsttime analgesic user plus updated upgraded version popons featuring iron include ingredient cause drowsiness gentle stomach folic acid calcium high need modernday people popons royal personalized people senior life source survey dentsu retail marketing inc based data collected 250 major drugstore nation wide participating survey panel store stage intended provide survey target analgesic antipyretic purchaser august 2011 july 2012 311790 people ageadjusted nutritive top 15 brand purchase amount support healthy life 32 shionogi annual report 2013 launch date japanese market oxycontin tablet oxinorm powder finibax intravenous drip infusion differin gel oxifast injection finibax solution kit intravenous topical acne vulgaris treatment oxycontin family drug drip infusion launched october 2008 cancer pain analgesic carbapenemtype antibiotic differin gel first topical retinoid oxycontin tablet launched july 2003 oxinorm powder launched september 2005 preparation japan indicated launched september 2009 oxifast injection launched shionogideveloped product acne vulgaris may 2012 finibax carbapenemtype antibiotic guideline cite differin gel highly combination shionogis 12hour sustainedrelease injection strong antibacterial activity recommended base acne vulgaris treat oxycontin tablet immediaterelease oxinorm powder pseudomonas aeruginosa ment treatment light severe enables cancer pain relieved effectively increasing expectation surround symptom following launch new oxifast injection ing product effectiveness treat patient difficulty taking oral drug ment serious intractable infection access treatment sepsis pneumonia peritonitis pirespa tablet rapiacta intravenous drip infusion idiopathic pulmonary fibrosis treatment antiviral drug influenza launched december 2008 launched january 2010 pirespa world first drug indicated rapiacta world first neuraminidase enzyme idiopathic pulmonary fibrosis inhibitor intravenous drip infusion pirespa expected inhibit decrease singledose intravenous drip infusion rapi vital capacity slow progression idio acta expected produce reliable treatment pathic pulmonary fibrosis benefit enabling used treat outpatient hospitalized patient age group infant elderly sale billion yen fiscal 2013 104 52 45 46 25 oxycontin family forecast fiscal 2012 102 50 40 45 20 finibax intravenous drip infusion finibax solution kit intravenous drip infusion fiscal 2011 89 47 37 34 14 differin gel pirespa tablet fiscal 2010 96 36 32 28 03 rapiacta intravenous drip infusion diagnostics diagnostic product business shionogi provides diagnostic reagent useful diagnosing assessing disease among purpose addition prescription drug business shionogi contributing wellbeing people diagnostic product business enabling early diagnosis treatment provision diagnostic reagent mi02 shionogi bnp launched december 2004 brightpoc flu shionospot bnp launched september 2006 quick influenza testing kit bnp kit launched september 2012 diagnostic product measure hormone bnp human brightpoc flu testing kit used quickly determine whether brain natriuretic peptide useful indicator diagnosing patient infected influenza virus kit provide assessing cardiac insufficiency therapeutic guideline cite testing positive test result within minute influenza type virus bnp blood level diagnostic reagent useful type b virus infection mean screening people sign cardiac insufficiency allerport tarc checkart quick testing system th2 chemokine tarc kit standard diabetes diagnosis marker launched february 2008 launched february 2013 allerport tarc support assessment severity atopic checkart testing system designed quickly measure dermatitis treatment benefit evaluation measuring hba1c hemoglobin a1c glucose level blood serum level tarc thymus activationregulated hba1c glucose indicator used diagnose chemokine believed play key role patho manage diabetes genesis atopic dermatitis shionogi annual report 2013 33 management shionogis business activity shionogis csr management system financial section corporate information activity fundamental policy csr executive officer yoshiaki kamoya shionogi group set forth goal corporate activity strive constantly supply best possible medicine protect health wellbeing patient serve company policy instituted 1957 eternal unwavering corporate philosophy statement vision value society operation pharmaceutical company inherently contribute society believe implementing philosophy promotes fulfillment social respon sibilities corporation also formulated shionogi charter conduct guide effort conducting corpo rate activity suited truly rich vibrant civil society corporate citizen phar maceutical manufacturer awareness social responsibility based high ethical value recent year expected company term csr corporate social responsibility activity line trend shionogi actively implementing csr activity creating inno vative pharmaceutical developing specialized human resource fulfill corporate respon sibility economy environment society earn trust understanding society good corporate citizen shionogi charter conduct company contributes maintenance improvement health people around world well comfortable life shionogi formulated charter conduct hope activity benefit stakeholder including patient shareholder general public lead growth individual employee shionogi employee pledge act spirit charter conduct senior management take responsibility serving role model rigorously ensuring charter conduct understood time pledge establish refine effective internal system conforming company rule 1 action corporate citizen 2 action pharmaceutical company 3 action shionogi 1 compliance 1 discovery original innovative pharma 1 raison detre 2 external relation ceuticals provision affordable 2 trust society 3 transaction distribution pharmaceutical 3 individual organiza 4 information management 2 drug development proper procedure tional growth disclosure 3 strict compliance pharmaceutical 4 respect individual 5 antisocial force related law regulation acceptance diversity 6 environmental protection 4 stable supply highquality pharmaceutical 5 tradition 7 social contribution activity 5 promotion proper use manufacture transformation sale 6 fulfilling satisfying workplace 34 shionogi annual report 2013 community relation public awareness activity ministry health labour welfare mhlw identified five medium using mean help improve public awareness disease category afforded top priority healthcare plan disease view enhancing patient awareness namely mental illness diabetes malignant neoplasm cerebrovascular facilitating early discovery disease ischemic heart disease shionogi engaging mass main public awareness activity disease description public awareness activity mental illness program promoting return work people suffering depression refer diabetes use website leaflet distribution forth provide information diabetic neuropathic pain malignant neoplasm cancer pain educational activity refer cerebrovascular disease use website mean provide information importance cholesterol manage ischemic heart disease ment order prevent onset arteriosclerotic disease heart attack angina stroke idiopathic pulmonary fibrosis use animated website video message specialist physician forth provide information designated intractable illness acne program supported dedicated nikibi wa hifuka e visit dermatologist acne website encour aging acne patient seek appropriate advice dermatologist rather suffering alone influenza use event website mean provide information wearing mask hay fever health management five major disease category helping depression sufferer return work cancer pain awareness campaign according mhlw every year half million people stay study found japan 36 patient suffering away work depression government figure put cancer pain receiving treatment pain nearly half combined economic cost suicide depression case 2678 receiving treatment made complaint concerning cancer pain billion suggested however reemployment depres health care professional see figure sion sufferer hampered dearth support scheme shionogi hold symposium health care professional cancer receptive workplace well factor patient family stress importance patient shionogi aim help find solution problem supporting informing health care professional pain symptom mean nikkei business publication inc depression rework working securing prompt treatment early relief cancer pain group group disseminates information various medium also operating dedicated website hosting symposium directed specialist physician counselor received pain relief never complained 36 pain 29 cancer pain management complained pain didnt receive pain relief 35 mental health symposium 2012 nagoya source mmj june 2008 vol 4 no6 p 534 shionogi annual report 2013 35 management shionogis business activity shionogis csr management system financial section corporate information activity community relation participation global health innovative socieour social contribution support association technology fund shionogi established socie 1997 company employee shionogi participating global health innovative technology employee labor union cooperate supporting socie member fund ghit fund contribute health people throughout voluntary social contribution activity socie provides assistance world especially developing world disaster japan specified japan disaster relief act ghit fund international nonprofit foundation dedicated well region overseas affected earthquake storm advancing development japan new medicine control volcanic eruption disease endemic developing country including three disaster also make annual devastating infectious disease hiv aid malaria tubercu donation various group losis neglected tropical disease ntds fiscal 2012 mark 15th anni participation ghit fund offer shionogi unique opportunity versary socie donated electronic strengthen healthcare developing country business piano item ronald focusing time development innovative medi mcdonald house charity japan cines improve life patient suffering infectious disease ronald mcdonald house charity japan including virus shionogi strives constantly accomplish mission established 1999 charity build ronald mcdonald house providing accommo provide innovative medicine patient developing nation dation sick child undergoing medical treatment family also aid indeed world ghit fund new important develops volunteer welfare medical care field element overall mission research grant two foundation shareholder investor communication hoansha foundation established march 5 1954 shionogi group discloses corporate data needed foundation established bequeath gisaburo earn appropriate share price proper timely manner shiono company second president conduct activity time promote twoway communication shareholder aim contributing advance pharmaceutical science providing investor use feedback management grant research contributes end fiscal 2012 top management hold semiannual annual financial result foundation provided grant 20 project across japan 2 briefing first thirdquarter conference call domestic special grant project kansai region also held presenta institutional investor analyst time also disclose tions announce result research company shionogi every quarter progress research development rd pharmaceutical research center sprc attended many vital pharmaceutical manufacturer furthermore senior manage inhouse external researcher ment convenes annual rd briefing way sharing infor foundation url httpwwwshionogicojpho mation regarding current status direction rd japanese whole also distribute audio recording financial result rd briefing website cell science research foundation additionally actively conduct managementled ir activity established march 17 1988 institutional overseas investor u uk asia opinion foundation established mark 110th anniversary question hear course investor relation activity shionogis founding activity aim contribute effort find japan overseas fed back relevant internal party used cause understand disease prevent treat condition management furthermore june advancing research cellular level life science field 2013 completely refreshed cor developing young researcher japan promoting international porate website one exchange fiscal 2012 foundation provided 10 research grant mean distribute informa provided support 4 young researcher study overseas tion revamp trying inviting sending researcher 6 international forum thereby enhance accessibility rd meeting contributing advance cell science research standability information needed foundation url httpwwwshionogicojpzaidan stakeholder well range japanese information available corporate website 36 shionogi annual report 2013 relationship employee list one five value shionogis action guideline respect individual mean maintaining maximum respect diverse individuality everyone involved shionogi human resource system employee childcare leave shorter human resource development working hour childcare flexible working hour people human resource system 200 shionogi put place human resource system place great employee emphasis producing result behavior modification childcare leave 150 aim developing strong individual growing organization shorter working hour childcare compete globally evaluation system feature grading according 100 flexible working hour duty remuneration reflects wage rate promotes growth individual contributing achievement organi 50 zational goal way promoting growth motivating 0 individual employee tackle achieve challenging target 2010 2011 2012 fy fair equitable personnel evaluation order employee grow job believe crucial occupational health safety properly evaluate achievement result develop mental health strategy ment performance duty give occupational health safety appropriate job remuneration benefit view order realize company policy shionogi recognizes importance shionogi clarifying evaluation standard disclosing information employee health safety work research production fair equitable basis providing extensive educational program facility chemical used safety health committee evaluator way shionogi increasing transparency workplace lead effort ensure chemical properly handled objectivity evaluation methodology addition giving well stored managed furthermore order prevent occupational appropriate feedback evaluation result company working injury illness caused facility equipment shionogi bolstering increase satisfaction evaluation system internal checking system time conduct rigorous safety inspection regularly work raise employee safety awareness human resource development concerning employee health shionogi promoting system shionogis basic stance human resource development people facilitate management working hour thereby create source company competitiveness support career framework preventing incidence chronically excessive work building right employee join shionogi hour also cooperate health insurance association ensure leave human resource development shionogi composed employee take part regular annual health checkup encour organic mix element including onthejob training offsite age employee receive testing adultonset gynecological training personal development believe growth illness way implementing measure individual employee lead growth organization maintain improve employee health promoting worklife balance mental health measure shionogi belief realizing company policy epitome address mental health shionogi specialized physician working achieving worklife balance thus promoting connection fulltime industrial physician established counseling various situation people face life raising child system includes outside employee assistance program eap caring relative engaging personal development policy way company implementing comprehensive state fulfilling one responsibility enhancing one skill range measure line japanese ministry health labour character human one feel satisfied fulfilled welfare four care policy selfcare managerial care onsite find greater richness one life result industrial staff health care external resourcebased care since december 2012 began issuing shionogi fiscal 2012 also conducting stress check employee worklife guide inhouse guidebook intro raise awareness mental physical health management duce various system designed bid prevent mental disorder support various life situation one way program provides support employee mental health promoting worklife balance shionogi worklife guide shionogi annual report 2013 37 management shionogis business activity shionogis csr management system financial section corporate information activity effort preserve environment effort preserve environment ensure employee understands importance environ promoting business activity shionogi group aware mental activity educate handling task large company important social responsibility give appropriate environmental impact commence work program consideration global local environment lessen envi cover general environmental education waste management chemical ronmental impact business activity established substance handling subject also prepared shionogi group environmental protection plan target accordance emergency situation earthquake fire disaster shionogi group basic environmental policy conduct hazardous substance leak range environmental preservation activity give consideration specify response procedure global environmental protection resource protection harmony communication reporting natural environment system well regularly con president ceo duct emergency response drill corporate executive meeting review response procedure chief environmental supervisor shionogi group central disaster drill kanegasaki plant environmental committee chief environmental management supervisor energy efficiency committee recognition kanegasaki plant sprc new wing environmental management shionogis kanegasaki plant received award minister committee environment recognition contribution sustainable business site subsidiary society 7th national convention promotion environmental environmental 3rs held october 2012 ministry environment committee committee 3r promotion forum production volume rose due department department increase production facility installation new equipment plant still able greatly improve recycling rate 38 92 maintain improving production environmental management system process well properly assessing separating different iso 14001 environmental audit type industrial waste shionogi acquired iso 14001 certification four business site building sprc4 sprc also widely large environmental impact namely three manufacturing divi acclaimed environmental friendliness design receiv sion kuise site settsu plant kanegasaki plant research ing many award include award excellence division shionogi pharmaceutical research center sprc osaka prefecture osaka sustainable architecture award subsidiary shionogi analysis center co ltd shionogi pharma well nikkeis kinki new chemical co ltd also obtained certification office promotion award due every year also receive audit external organization factor facility fiscal 2012 certification renewed following audit japan functionality consideration chemical quality assurance ltd furthermore environmental audit environment conducted manufacturing plant research laboratory domestic production subsidiary confirm status environmental management satisfactory environmentrelated law regula sprc4 osaka tions complied environmental risk prop erly managed forth international standard environmental management system target phase 4 shionogi group environ mental protection plan fiscal 2012 result compliance law regulation education present striving reduce group entire environmental training impact implementing initiative phase 4 shionogi japan wide range environmental regulation shionogi group environmental protection plan fiscal 2011 fiscal 2015 group identifies law regulation governing activity shar target result activity fiscal 2012 follows ing pertinent information business site well conducting education program creating manual ensure legal compliance 38 shionogi annual report 2013 n fiscal 2012 result benchmark 95679 100 1 promote measure conserve manufacturing research division took various fiscal year actual fy2009 energy counter global step upgrading highly efficient boiler fy2011 actual 92558 967 warming power supply equipment improving air fy2012 actual 89155 1047 reduce co2 emission 23 compared conditioning control time domestic target 73673 941 fiscal 2005 benchmark year fiscal 2020 production subsidiary switched fuel oil gas fiscal year reduce basic unit energy boiler upgraded step led annual average 1 co2 emission ton 68 reduction co2 emission compared promote introduction highly energy benchmark fiscal year basic unit energy basic unit energy v fy2009 efficient equipment facility affected start operation three new wing basic unit energy calculated dividing energy kanegasaki plant alongside factor usage production volume total floor area etc continue effort improve energy efficiency n fiscal 2012 result fy2010 actual 4961 20 2 strengthen conservation resource worked reduce waste formulation waste disposal measure fy2011 actual 4744 27 process manufacturing department reduce amount waste generated 4564 10 compared fiscal 2010 benchmark promoted 3rsreduce reuse recycle fy2012 actual 20 year 20 reduction fiscal 2020 including reusing solvent recycling fy2015 target 4442 promote zero emission waste liquid fy2020 target 3986 waste sent landfill final disposal divided waste generated ton landfill disposal rate total waste generated 1 defined zero emission n fiscal 2012 result fy2010 actual 1136 3 strengthen management set voluntary control level chemical chemical substance stricter regulatory level fy2011 actual 889 reduce atmospheric emission dichloro controlling emission fiscal 2012 atmospheric fy2012 actual 1009 methane manufacture active pharma emission dichloromethane increased ceutical ingredient apis 50 compared kanegasaki plant due defective facility however fy2015 target 568 fiscal 2010 benchmark year continue look way achieving control use atmospheric emission atmospheric emission dichloromethane ton emission reduction target chemical substance promote proper treatment manage ment polychlorinated biphenyls pcbs n fiscal 2012 result 4 promote understanding conducted employee training part environmental activity aware biodiversity ness biodiversity accordance fundamental philosophy guideline properly preserve expand endangered conduct concerning biodiversity formulated japan pharmaceutical plant specie company botanical manufacturer association addition research division conducted research garden conformity law concerning conservation sustainable use conduct education biodiversity biological diversity regulation use living modified organism asiasarum dimidiatum related law regulation invasion alien specie act aburahi facility botanical garden endangered plant maintained managed variety endangered plant looking increasing number plant n fiscal 2012 result 171 5 promote introduction order reduce co2 exhaust gas emission fy2010 actual 431 397 lowemission vehicle raising fuel efficiency making progress fy2011 actual 223 489 456 use hybrid electric vehicle car introducing hybrid vehicle mr fiscal 2012 377 lent mr except cold region fy2012 actual 471 800 hybrid vehicle accounted 800 450 vehicle excluding cold region japan 312 fy2015 target 450 100 percentage point fiscal 2011 reflecting large number newly introduced vehicle ev hb car lent mr ratio ev hb ev hb mean electric vehicle hybrid vehicle respectively thirdparty opinion expert institute environmental management accounting iema provide u opinion effort improve reliability transparency disclosure environmental activity also receive advice environ mental friendliness environmental management status future activity shionogi annual report 2013 39 management shionogis business activity shionogis csr activity management financial section corporate information system corporate governance shionogi group recognizes social mission continually discover develop provide useful safe medicine help improve health people medical treatment around world well quality life shionogi also recognizes continuously faithfully accomplishing mission increase corporate value accordingly belief strongly carrying sound transparent management practice corporate governance system established corporate governance system shionogi group adopted company board auditor board auditor five member including three outside corporate governance system board director five member member board auditor order ensure greater transpar including three outside director order enhance manage ency fairness member board auditor audit director ment transparency accountability stakeholder furthermore performance duty meeting board director cor company established nomination advisory committee porate executive meeting compensation advisory committee advisory body board moreover company introduced corporate officer system director committee chaired outside director ensuring allow management policy reflected operation without selected director vetted evaluated fair honest delay built flexible operational execution structure able perspective multiple angle including assessment aptitude rapidly respond change operating environment furthermore impact management quality work performance appropriate corporate executive meeting unit created conduct delibera ness compensation tions regarding operational execution issue composed director standing member board auditor corporate officer responsible operation corporate governance structure april 2013 amount remuneration director annual general meeting shareholder member board auditor fiscal 2012 appointment appointment appointment amount remuneration paid dismissal dismissal dismissal nominating million advisory report audit board person base stock board committee director category remunerated remuneration bonus option total auditor director compensation director 6 186 26 28 241 member independent advisory board supervision outside director accounting auditor committee election among director 3 33 33 auditor dismissal accounting member audit representative compliance board auditor 5 91 91 director committee outside member corporate board internal executive auditor among internal audit meeting member control corporate officer board auditor 3 35 35 department department group company total 11 277 26 28 333 outside director outside member board auditor selection policy outside director outside member board auditor conflict interest company individ selected individual know role outside director outside ual outside director outside member board auditor member board auditor give frank opinion risk conflict interest general shareholder advice company management right time selected individual outstanding insight ability based selected individual personality professional background experience specialist expertise relating management insight quality sincerely valued properly demonstrate insight ability company management team also stakeholder 40 shionogi annual report 2013 message outside director akio nomura since appointment outside director felt shionogi pharmaceutical manufacturer conduct corporate activity based high ethical value accordance company policy state shionogi strives constantly supply best possible medicine protect health wellbeing patient serve order company earn trust society continuously develop must actively disclose information ensuring transparency decisionmaking shionogis board director make open fair manage ment decision always mindful accountability draw experience corporate manager place importance neutrality independent direc tor work increase corporate value objective perspective also work ensure shionogi develops contributes broadly society teppei mogi economic globalization gather pace important japanese company comply various law regulation country around world antitrust law u foreign corrupt practice act fcpa course observe law regulation japan shionogis management must sufficiently aware overseas law regulation executing business company develops business globally using experience related international legal affair contribute outside director refinement operation global compliance risk management system time offer appropriate advice legal focus management decision katsuhiko machida manufacturing industry including pharmaceutical business precious industry resourcepoor country like japan role play extremely large one indeed however amid increasing uncertainty surrounding global economy escalating competition greater demand swift management decisionmaking weighs risk reward based management experience global manufacturing company objective outside perspective shareholder stakeholder determined contribute even objective transparent man agement shionogi maintaining overarching perspective stakeholder reason selection outside director outside member board auditor name reason selection attendance outside akio nomura mr nomura abundant experience broad discernment senior corporate executive attended 11 board director meeting director company belief make management decision placing importance objectivity impartiality management contribute highly transparent management independent director teppei mogi mr mogi abundant experience professional knowledge attorney law attended 11 board director meeting company belief use experience knowledge make management deci sion placing priority observance social norm law ordinance contribute highly transparent management independent director katsuhiko machida mr machida abundant experience broad discernment senior corporate executive attended 9 board director meeting global manufacturing business company belief make management deci appointment june 27 2012 sion placing importance objectivity impartiality management contribute highly transparent management independent director outside takeharu nagata mr nagata abundant experience broad discernment senior corporate executive attended 11 board director meeting member company belief properly carry audit duty providing advice regarding attended 7 board auditor meeting legality propriety operation executed director board shinichi yokoyama mr yokoyama abundant experience broad discernment senior corporate executive attended 11 board director meeting company belief properly carry audit duty providing advice attended 7 board auditor meeting auditor regarding legality propriety operation executed director kenji fukuda mr fukuda abundant experience professional knowledge attorney law attended 11 board director meeting company belief use experience knowledge properly carry audit duty attended 7 board auditor meeting providing advice regarding legality propriety operation executed director koichi tsukihara mr tsukihara abundant experience broad discernment senior corporate executive appointed june 26 2013 company belief properly carry audit duty providing advice regarding legality propriety operation executed director shionogi annual report 2013 41 management shionogis business activity shionogis csr activity management financial section corporate information system corporate governance status audit execution member board auditor receive report detail internal audit accounting audit independent auditor necessary join member board auditor receive regular monthly report accounting audit conducted independent auditor status result internal audit internal control exchange opinion respond way department company internal auditing department exchange opinion respond way furthermore mem name certified public accountant cpa bers board auditor cooperate internal control independent auditor department conduct investigation carry work name independent quickly address issue internal control perspective name cpa auditor designated limited akihiko masuda liability partner ernst young hideki maekawa shinnihon llc engagement partner assistant audit work nine cpa seven people including people passed cpa examination system expert strengthening internal control system accordance basic policy building internal control system addition shionogi make sincere effort ensure reli system approved board director based company ability financial reporting time comply act shionogi established system ensuring appropriateness internal control report system financial instrument operation board director annually evaluates state exchange act shionogi strengthening internal control financial management internal control system past year based reporting shionogi group whole work improve evaluation revise basic policy augment internal control quality management control framework information disclosure accordance company disclosure policy shionogi appropriate fair manner stakeholder order enhance group continuously discloses corporate information timely management transparency company widely trusted society risk management shionogi recognizes intrinsic risk factor organizational situation shionogi formulated compendium pertaining specifi unit associated activity determines response strategy cally compendium disaster pandemic corporate scandal work avoid mitigate risk response policy well bcp guideline based crisis management policy accor important risk could significantly impact company manage dance shionogi promoting crisis management process ment discussed corporate executive meeting emphasize respect human life demonstrate consideration meeting necessary measure implemented regarding risk contribution local community mitigate potential damage associated disaster accident corporate scandal corporate value 42 shionogi annual report 2013 thorough compliance shionogi work instill importance compliance shionogi bureau compliance committee draft compliance mea group employee request compliance performance accordance sure proposal group whole provides support shionogi group compliance policy order ensure compli promotion activity department unit well run compli ance law regulation ethical behavior business activi ance training program employee april 2013 company tie specifically led compliance committee chaired formulated disseminated shionogi code practice president company engages following type activity time distributed revised version shionogis compliance hand company designates compliance manager depart book employee providing reminder regarding compliance ment unit along compliance promoter assistant shionogi also work improve internal audit strengthen officer take step identify prevent compliance risk based monitoring verify effectiveness internal control system compliance risk management action plan department unit time working discover early prevent compliance time work increase effectiveness compli violation fully utilizing internal control system ance assurance integrated management across company progress reported compliance risk management action report compliance promotion structure april 2013 president ceo corporate executive meeting compliance committee report cooperation general administration subsidiary corporate scandal risk subsidiary management shionogis compliance handbook deliberation committee department risk analysis assessment measure proposal countermeasure formulation implementation support cooperation compliance manager manager division unit assistance compliance promoter least one appointed division unit shionogi annual report 2013 43 management shionogis business activity shionogis csr activity management financial section corporate information system member board june 26 2013 earning trust stakeholder shionogi aim corporate entity trusted stakeholder including shareholder patient family medical community directly addressing various issue transparency high ethical value director front row left motozo shiono isao teshirogi back row left teppei mogi akio nomura katsuhiko machida chairman board 1972 joined company 1987 managing director company 1996 representative executive director representative director 1984 general manager marketing planning department 1990 senior managing director company 1999 president company motozo shiono 1984 director company 1996 general manager agro vet industrial chem 1999 general manager corporate planning division 1987 general manager accounting department division 2008 chairman board incumbent president ceo 1982 joined company 2004 executive officer executive general manager 2007 senior executive officer isao teshirogi phd 1999 general manager corporate planning department pharmaceutical research development division 2008 president ceo incumbent general manager secretary office 2006 senior executive officer executive general 2002 director company manager pharmaceutical research development 2002 general manager corporate planning department division outside director 1998 representative director president osaka gas 2003 representative director chairman osaka gas 2009 outside director company incumbent akio nomura co ltd co ltd 2000 director west japan railway company 2008 outside director royal hotel ltd incumbent outside director 1989 registration attorney law 2004 professor kwansei gakuin university law school 2009 outside director company incumbent teppei mogi 1994 partner ohebashi law office incumbent 2005 parttime instructor kobe university graduate 2010 parttime instructor kwansei gakuin 2002 partner ohebashi lpc partner incumbent school law incumbent university law school incumbent outside director 1998 president sharp corporation 2008 chairman chief executive officer sharp 2012 corporate advisor sharp corporation katsuhiko machida 2007 chairman sharp corporation corporation 2012 outside director company incumbent 2008 outside director sekisui house ltd incumbent 2010 chairman sharp corporation 2013 special advisor sharp corporation incumbent 2012 director corporate advisor sharp corporation 44 shionogi annual report 2013 member board auditor left shinichi yokoyama sachio tokaji mitsuaki ohtani koichi tsukihara kenji fukuda standing member 1975 joined company 2000 general manager pharmaceutical development division 2002 executive general manager pharmaceutical board auditor 1998 director company general manager strategic development department research development division general mitsuaki ohtani 1998 general manager clinical research 2001 executive general manager pharmaceutical research manager discovery research laboratory department general manager product development division general manager discovery 2004 standing member board auditor phd research laboratory general manager strategic company incumbent development department development department standing member 1970 joined company 2004 corporate officer general manager accounting 2007 executive officer corporate business manage board auditor 1998 general manager accounting department financial department general manager international ment executive sachio tokaji 2002 director company business department 2008 director company senior executive 2002 general manager accounting financial 2006 corporate officer corporate business management officer department executive general manager accounting financial 2011 standing member board auditor department company incumbent 2004 corporate officer general manager accounting financial department outside member 2001 president sumitomo life insurance 2007 chairman representative director sumitomo life 2010 outside corporate auditor sumitomo chemical board auditor company insurance company incumbent co ltd incumbent shinichi yokoyama 2003 outside corporate auditor nec corporation 2008 outside member board auditor company incumbent outside member 1984 registration attorney law 2009 vice president osaka bar association 2011 outside member board auditor board auditor 1984 joined dojima law office 2009 governor japan federation bar association company incumbent kenji fukuda 1987 partner dojima law office incumbent 2009 visiting professor osaka university law school outside member 2005 deputy president executive officer 2006 representative director president 2012 director chairman sumitomo mitsui card board auditor sumitomo mitsui banking corporation sumitomo mitsui card co ltd co ltd incumbent koichi tsukihara 2005 vice president executive managing 2011 representative director chairman sumitomo mitsui 2012 outside director gurunavi inc incumbent officer sumitomo mitsui financial group card co ltd 2013 outside member board auditor company incumbent senior executive officer executive officer executive officer executive officer corporate officer takuko sawada takuo fukuda ryuichi kume yoshiaki kamoya hirosato kondo corporate phd phd officer corporate officer corporate officer corporate officer corporate officer corporate officer corporate officer corporate officer corporate officer kohji hanasaki takayuki yoshioka kiyoshi nagata masaaki goshima akio tsubokura masaaki takeyasu john keller phd shinya matsuzawa phd phd phd shionogi annual report 2013 45 management shionogis business activity shionogis csr activity management system financial corporate information section tenyear consolidated financial highlight shionogi co ltd consolidated subsidiary million yen 2004 2005 2006 2007 year ended march 31 net sale 200485 199365 196389 199759 cost sale 79856 74069 68708 67542 selling general administrative expense 100337 96567 98455 103354 operating income 20292 28729 29226 28863 income income tax minority interest 5178 31655 38798 31723 net income 2204 18942 22735 18595 research development expense 29808 29409 32257 37456 capital investment 5853 5001 11132 11107 depreciation amortization 9705 9412 8653 8798 march 31 property plant equipment net 71993 68191 64251 67815 total asset 376161 396999 427683 429569 total longterm liability 49005 27783 38371 36282 total net asset 292387 300065 337434 345752 per share amount net income 606 5464 6655 5461 net asset 84453 87979 98976 101473 dividend 850 1200 1600 1600 equity ratio 777 755 788 804 return equity roe 08 64 71 54 payout ratio 1403 220 240 293 note 1 u dollar figure calculated convenience rate 9401 us100 approximate rate exchange march 31 2013 2 ﬁscal year ended march 31 2007 company adopted new accounting standard presentation net asset balance sheet reclassiﬁes former shareholder equity valuation translation adjustment minority interest total net asset figure ﬁscal year year ended march 31 2006 calculated conformity new standard 46 shionogi annual report 2013 thousand million yen u dollar 2008 2009 2010 2011 2012 2013 2013 214268 227512 278503 282350 267275 282904 3009297 68594 70929 76264 81737 77753 78575 835815 105275 124568 149801 153721 142519 145480 1547495 40399 32015 52438 46892 47003 58849 625987 39963 30786 58541 33135 41495 58307 620221 25064 15661 38626 20027 27102 66728 709797 40290 52822 51808 50921 53599 53021 563993 13069 10875 12547 17967 13233 11447 121764 10666 13468 18048 17966 16282 11912 126710 70378 71812 62448 70221 74282 78474 834741 413704 501853 540762 523242 522162 574882 6115115 29024 114955 131956 115326 92900 53042 564216 342236 310094 341976 328096 347198 423633 4506255 yen u dollar 7421 4675 11533 5980 8093 19925 212 102031 92443 101971 97969 102783 125444 1334 2200 2800 3600 4000 4000 4200 045 827 617 632 627 659 731 73 48 119 60 81 175 296 599 312 669 494 211 shionogi annual report 2013 47 management shionogis business activity shionogis csr activity management system financial corporate information section management discussion analysis overview result sale prescription drug japan fiscal year ended march 31 2013 increased slightly year year despite effect nhi drug price revision shionogi group addition previously volatile result u operation stabilized shionogi group benefited groupwide cost reduc tions result factor shionogi group achieved record operating income net sale result gross profit increased 78 year year net sale increased 58 year year 282904 million 204329 million 1 domestic sale prescription drug sale eight strategic product centered three core operating expense operating income strategic product hyperlipidemia treatment crestor selling general administrative sga expense increased hypertension treatment irbetan antidepressant drug 21 however operating income increased 252 year year cymbalta increased 150 84219 million compen 58849 million due factor including higher net sale sated lower sale existing product due nhi drug price improved gross margin ongoing cost reduction improved revision factor led overall increase earnings shionogi inc domestic sale prescription drug 2 export overseas subsidiary income expense export overseas subsidiary sale increased substantially sale fiscal 2012 shionogi recorded net expense 542 increased substantially year year u subsidiary shionogi million compared net expense 5508 million inc achieved stable operation throughout fiscal year fiscal 2011 addition chinabased pharmaceutical company co result viiv agreement covering hiv drug pharmaceutical technology holding limited co also con shionogi group recognized income 40434 million tributed full year sale gain exchange investment security difference 3 royalty income carrying value shionogi group equity position crestor royalty income decreased astrazenecas global shionogiviiv healthcare lp market value fair value sale crestor decreased 2012 however total royalty income 10 equity position viiv addition revising agree increased year year 69846 million due onetime ment shionogi considered reallocation management licensing fee alzheimers disease treatment resource u operation tested impairment goodwill sale right associated product shionogi inc han gross profit dle result shionogi recognized impairment loss fixed cost sale increased 11 yearonyear term 78575 asset 40836 million million cost sale ratio decreased 291 278 due increase sale u operation cost sale income income tax minority interest ratio low net income income income tax minority interest increased 405 58307 million including income tax adjustment net sale operating income billion yen billion yen 3000 600 588 2785 2824 2829 2673 524 2275 469 470 2000 400 320 1000 200 0 0 2008 2009 2010 2011 2012 fy 2008 2009 2010 2011 2012 fy 48 shionogi annual report 2013 income tax negative 8531 million decrease 1593 improving success rate moving nonclinical clinical year year reflected large decline income tax due trial october 2012 shionogi group licensed treatment loss valuation stock affiliate booked alzheimers disease novel mechanism action nonconsolidated basis result aforementioned impair johnson johnson group company excellent experience ment shionogi inc expertise field alzheimers disease moreover net income increased 1462 66728 million net shionogi group energetically collaborates university income ratio 236 compared 101 previous research institution japan around world sustain fiscal year net income per share increased 8093 discovery innovative new drug 19925 2 development activity present shionogi group developing strong pipeline segment information includes latestage development drug alleviating shionogi group operates single business segment related opioidinduced adverse effect s297995 allergic rhinitis prescription drug involving research development pur treatment s555739 february 2012 shionogi group chasing manufacturing distribution related business established wholly owned subsidiary shionogi limited prescription drug shionogi performs analysis sale london united kingdom development base europe product evaluation performance group company shionogi group move forward faster effec decision business strategy allocation management tive triregional development united state europe resource especially allocation research development asia enable rapid supply drug global market expense made groupwide basis therefore disclosure 3 inlicensing product technology segment information year ended march 31 2013 october 2012 shionogi group kotobuki omitted pharmaceutical co ltd nagano prefecture concluded license agreement covering worldwide right develop manufac research development expense ture commercialize cholesterol absorption inhibitor koto shionogi group aim achieve worldclass research produc buki code name kt6971 owned kotobuki product tivity quickly supply pharmaceutical global market expected lower serum cholesterol level selectively inhibit conducting research development rd activity group ing cholesterol transporter small intestine shionogi quickly identifies unmet medical need medical need group committing providing new option treating meta addressed reason including lack effective treatment bolic syndrome one targeted therapeutic area enhances strength small molecule drug discovery result activity overall group rd expense deploys various leadingedge technology develop large mol fiscal 2012 totaled 53021 million ecule drug continuously supply innovative pharmaceutical patient worldwide cash flow 1 research activity fiscal 2012 net cash provided operating activity increased july 2011 shionogi group completed shionogi phar 4552 million compared previous fiscal year 59276 maceutical research center sprc aim consolidating million income income tax minority interest strengthening research function sprc energetically con increased depreciation amortization noncash ducting activity aim strengthening organiza item decreased tional cooperation increasing candidate development net income rd expense billion yen billion yen 800 600 528 518 536 530 667 509 600 400 400 386 271 200 200 200 157 0 0 2008 2009 2010 2011 2012 fy 2008 2009 2010 2011 2012 fy shionogi annual report 2013 49 management shionogis business activity shionogis csr activity management system financial corporate information section management discussion analysis net cash used investing activity decreased 18330 million total liability amounted 151249 million decrease compared previous fiscal year 19960 million 23715 million primarily reflected loss carry forward absence use cash connection co acquisition discussed reduced accrued income tax fiscal 2011 main us cash purchase property group redemption bond repayment longterm debt plant equipment connection construction net asset totaled 423633 million 76435 million year betalactam injectable drug facility new production facility year total shareholder equity increased 53336 million highpotency active pharmaceutical ingredient 428773 million mainly net increase retained net cash used financing activity increased 9938 million earnings addition net income deduction compared previous fiscal year 37687 million dividend accumulated comprehensive loss net decreased result factor included redemption bond payable 22559 million 8662 million year earlier due repayment debt payment dividend impact exchange rate stock price share subscription right result cash cash equivalent march 31 2013 increased 64 million minority interest increased 476 million increased 2855 million 101543 million reflecting various factor ratio total net asset total asset increased 659 731 capital investment capital investment shionogi group fiscal 2012 totaled dividend 11447 million 1786 million 135 year year shionogi aim raise dividend steadily line performance company invested 10509 million mainly manufactur proactively making business investment increase corpo ing facility expansion including construction betalactam rate value medium longterm perspective shionogi injectable drug facility new production facility high group making steady progress growth initiative potency active pharmaceutical ingredient furthermore total therefore raised target consolidated dividend payout 938 million invested consolidated subsidiary shionogi inc ratio 40 return profit shareholder elsewhere shionogis article incorporation stipulate twiceyearly distri butions retained earnings interim final dividend wher asset liability net asset ever possible general meeting shareholder must approve march 31 2013 total asset stood 574882 million final dividend board director approves 52720 million march 31 2012 current asset interim dividend increased 25913 million year year 266845 million consolidated net income fiscal 2012 includes reduced tax increase due mainly loss carry forward company payment connection loss valuation stock resulted increase deferred income tax income affiliate excluding onetime tax effect based tax receivable noncurrent asset increased 26807 million policy shionogi decided increase yearend cash dividend year earlier 308037 million mainly increase fiscal 2012 2 22 per share forecast beginning investment security resulting acquisition viiv fiscal year together interim cash dividend total share outweighed decrease goodwill marketing right due annual dividend 42 per share consolidated dividend impairment payout ratio 211 total asset billion yen 6000 5749 5408 5232 5222 5019 4000 2000 0 2008 2009 2010 2011 2012 fy 50 shionogi annual report 2013 business risk main type risk might significant impact 5 risk dependence certain product shionogi group management performance financial condi shionogi group obtains approximately 42 product sale tion listed royalty income two product crestor flomox forwardlooking statement text reflect group fiscal 2012 incidence unexpected factor judgment march 31 2013 cause drop discontinuation sale one product possibility might impact 1 systemic regulatory risk group performance pharmaceutical industry revision national health insurance nhi system considered including revision 6 intensification global competition nhi drug price system trend could affect result global competition involving nonjapanese company phar shionogi group addition increase strictness maceutical industry rd sale operation becoming increas japanese overseas regulation concerning item ingly intense development manufacture pharmaceutical could present group additional expense make difficult prod 7 risk alliance company ucts comply regulation possibility shionogi group engages diverse form alliance might impact group performance company respect joint research joint development joint marketing activity including cooperation 2 risk adverse drug reaction form cooperative research project cooperative development pharmaceutical entail risk unanticipated adverse drug reac project inlicensing outlicensing technology tions could involve termination sale product recall cooperative marketing project situation change outcome could affect result shionogi group eliminate cooperative relationship might impact group performance 3 pharmaceutical rd risk pharmaceutical rd requires substantial commitment resource 8 risk natural disaster pandemic time addition new drug subject numerous uncer sudden occurrence natural disaster unforeseen tainties prior start actual sale incident pandemic could dictate closure plant labora tory business site shutdown plant 4 intellectual property risk could affect result shionogi group shionogi group us patent intellectual property protect pharmaceutical discovers generate income 9 capital market foreign exchange risk however various type intellectual property may unable fluctuation stock foreign exchange market exceed provide adequate protection may infringe intellectual projected range could affect result financial position property third party shionogi group furthermore expiry intellectual property right pat ents pharmaceutical developed shionogi launch 10 risk sale generic expiry could affect result addition abovelisted risk shionogi group business shionogi group activity involve risk lawsuit risk related regulatory political economic factor diverse risk list risk include type risk shionogi group exposed main patent litigation shionogi group interested party july 2013 country product technology plaintiff defendant court filing date current status high court shionogi patent holder 8 generic product sale established june 2013 u crestor december 2007 astrazeneca company apotex inc etc settled cobalt pharmaceutical inc march 2013 watson pharmaceutical inc shionogi patent holder u crestor actavis inc october 2010 settled march 2013 astrazeneca egis pharmaceutical fortamet shionogi lupin ltd settled mylan inc march 2013 u january 2009 shionogi inc product andrx corp patent holder mylan inc settled lupin ltd may 2013 shionogi patent holder doribax u peninsula pharmaceutical inc sandoz inc december 2011 decision pending japan product name finibax janssen pharmaceutical inc doribax sandoz inc u shionogi patent holder december 2012 decision pending japan product name finibax hospira inc shionogi annual report 2013 51 management shionogis business activity shionogis csr activity management system financial corporate information section consolidated financial statement consolidated balance sheet shionogi co ltd consolidated subsidiary march 31 2013 thousand u dollar million yen note 5 2013 2012 2013 asset current asset cash cash equivalent note 9 12 101543 98688 1080130 shortterm investment note 6 12 4465 6296 47495 note account receivable note 12 affiliate 697 880 7414 trade 67212 64688 714945 3067 4724 32624 allowance doubtful account 12 17 128 70964 70275 754855 inventory note 7 49328 50121 524710 deferred income tax note 14 21036 9044 223763 current asset 19509 6508 207521 total current asset 266845 240932 2838474 property plant equipment land note 24 9769 9856 103914 building structure note 24 119343 120207 1269471 machinery equipment vehicle 80982 82433 861419 furniture fixture 36894 37381 392448 construction progress 7525 5777 80045 accumulated depreciation 176039 181372 1872556 property plant equipment net 78474 74282 834741 investment asset investment security note 6 12 121077 55151 1287916 investment affiliate note 12 1552 8418 16509 prepaid pension cost note 15 25272 22809 268822 goodwill note 13 40293 63573 428603 marketing right note 13 24048 36664 255803 longterm prepaid expense 4493 6851 47793 deferred income tax note 14 5732 6238 60972 asset 7096 7244 75482 total investment asset 229563 206948 2441900 total asset 574882 522162 6115115 52 shionogi annual report 2013 thousand u dollar million yen note 5 2013 2012 2013 liability net asset current liability note account payable note 12 affiliate 1434 1231 15254 trade 9301 7382 98936 construction 2552 3844 27146 shortterm bank loan note 8 12 7500 79779 current portion longterm debt note 8 12 31500 24000 335071 allowance employee bonus 7135 6746 75896 provision sale return 6459 5357 68705 accrued expense 20599 15219 219115 accrued income tax note 12 14 1079 9891 11478 deferred income tax note 14 2 21 current liability note 9 10646 8394 113243 total current liability 98207 82064 1044644 longterm liability longterm debt note 8 12 30028 69000 319413 accrued retirement benefit employee note 15 8995 8793 95681 deferred income tax note 14 12757 7730 135698 longterm account payableother 219 6244 2329 longterm liability 1043 1133 11095 total longterm liability 53042 92900 564216 contingent liability note 10 net asset shareholder equity note 11 common stock authorized 1000000000 share issued 351136165 share 2013 2012 21280 21280 226359 capital surplus 20227 20227 215158 retained earnings 407008 353676 4329412 less treasury stock cost 19742 19746 209999 total shareholder equity 428773 375437 4560930 accumulated comprehensive income loss net unrealized holding gain security 16055 7729 170780 deferred loss hedge note 28 450 141 4787 translation adjustment 24267 38809 258132 accumulated comprehensive loss net 8662 31221 92139 share subscription right 123 59 1308 minority interest 3399 2923 36156 total net asset note 27 423633 347198 4506255 total liability net asset 574882 522162 6115115 see accompanying note consolidated financial statement shionogi annual report 2013 53 management shionogis business activity shionogis csr activity management system financial corporate information section consolidated financial statement consolidated statement income shionogi co ltd consolidated subsidiary year ended march 31 2013 thousand u dollar million yen note 5 2013 2012 2013 net sale note 24 29 282904 267275 3009297 cost sale note 16 24 78575 77753 835815 gross profit 204329 189522 2173482 selling general administrative expense note 17 145480 142519 1547495 operating income 58849 47003 625987 income expense interest dividend income 2073 1634 22051 interest expense 1123 1330 11946 loss disposal property plant equipment 556 330 5914 gain sale land 228 587 2425 gain exchange investment security 40434 430103 gain sale investment security note 6 1019 153 10839 loss sale fixed asset note 18 329 3500 impairment loss fixed asset note 13 40836 1557 434379 loss disaster note 19 270 1166 2872 litigation settlement note 20 489 5202 contract termination cost 159 1346 1691 loss devaluation investment security note 6 124 426 1319 special retirement benefit expense note 21 90 957 business structure improvement expense note 22 844 net 320 883 3404 542 5508 5766 income income tax minority interest 58307 41495 620221 income tax note 14 current 764 20339 8126 deferred 9295 5947 98872 8531 14392 90746 income minority interest 66838 27103 710967 minority interest 110 1 1170 net income note 27 66728 27102 709797 see accompanying note consolidated financial statement 54 shionogi annual report 2013 consolidated statement comprehensive income shionogi co ltd consolidated subsidiary year ended march 31 2013 thousand u dollar million yen note 5 2013 2012 2013 income minority interest 66838 27103 710967 comprehensive income note 23 net unrealized holding gain security 8326 3996 88565 deferred loss gain hedge 309 148 3287 translation adjustment 14907 1766 158568 comprehensive income net 22924 2378 243846 comprehensive income 89762 29481 954813 comprehensive income attributable shareholder shionogi co ltd 89286 29518 949750 minority interest 476 37 5063 see accompanying note consolidated financial statement consolidated statement change net asset shionogi co ltd consolidated subsidiary year ended march 31 2013 million yen total total net unrealized accumulated share common capital retained treasury shareholder holding gain deferred loss translation compre subscription minority total stock surplus earnings stock cost equity security hedge adjustment hensive loss right interest net asset balance april 1 2011 21280 20227 339970 19744 361733 3733 289 37081 33637 328096 net income 27102 27102 27102 dividend 13396 13396 13396 purchase treasury stock 2 2 2 change 3996 148 1728 2416 59 2923 5398 balance april 1 2012 21280 20227 353676 19746 375437 7729 141 38809 31221 59 2923 347198 net income 66728 66728 66728 dividend 13395 13395 13395 disposal treasury stock 8 8 8 purchase treasury stock 4 4 4 change 1 1 8326 309 14542 22559 64 476 23098 balance march 31 2013 21280 20227 407008 19742 428773 16055 450 24267 8662 123 3399 423633 thousand dollar note 5 total total net unrealized accumulated share common capital retained treasury shareholder holding gain deferred loss translation compre subscription minority total stock surplus earnings stock cost equity security hedge adjustment hensive loss right interest net asset balance april 1 2012 226359 215158 3762110 210041 3993586 82215 1500 412818 332103 628 31092 3693203 net income 709797 709797 709797 dividend 142485 142485 142485 disposal treasury stock 85 85 85 purchase treasury stock 43 43 43 change 10 10 88565 3287 154686 239964 680 5064 245698 balance march 31 2013 226359 215158 4329412 209999 4560930 170780 4787 258132 92139 1308 36156 4506255 see accompanying note consolidated financial statement shionogi annual report 2013 55 management shionogis business activity shionogis csr activity management system financial corporate information section consolidated financial statement consolidated statement cash flow shionogi co ltd consolidated subsidiary year ended march 31 2013 thousand u dollar million yen note 5 2013 2012 2013 operating activity income income tax minority interest 58307 41495 620221 adjustment depreciation amortization 11912 16282 126710 impairment loss fixed asset 40836 1557 434379 amortization goodwill net 3204 3426 34081 loss gain sale disposal property plant equipment 656 263 6978 gain sale investment security 1019 153 10839 loss devaluation investment security 124 426 1319 gain exchange investment security 40434 430103 decrease provision loss disaster 1492 decrease increase accrued retirement benefit employee 2261 741 24051 interest dividend income 2073 1634 22051 interest expense 1123 1330 11946 1935 2600 20583 change operating asset liability note account receivable 1705 6286 18136 inventory 1233 1296 13116 current asset 1395 8914 14839 note account payable 1965 4954 20902 accrued expense 7986 8854 84948 current liability 5177 4931 55068 subtotal 78007 77188 829774 interest dividend received 2072 1654 22040 interest paid 1077 1230 11456 income tax paid 19726 22888 209829 net cash provided operating activity 59276 54724 630529 56 shionogi annual report 2013 thousand u dollar million yen note 5 2013 2012 2013 investing activity increase shortterm investment 5159 4662 54877 proceeds sale redemption shortterm investment 9451 7962 100532 increase investment security 4275 4061 45474 proceeds sale redemption investment security 3828 4178 40719 purchase property plant equipment 12769 18313 135826 purchase intangible asset 8516 10927 90586 increase investment affiliate 2751 3578 29263 acquisition investment subsidiary resulting change scope consolidation 12639 231 3750 2457 net cash used investing activity 19960 38290 212318 financing activity increase shortterm bank loan net 7500 79779 proceeds longterm debt 26 277 repayment redemption longterm debt 31500 14000 335071 purchase treasury stock 4 3 43 cash dividend paid 13378 13376 142304 331 370 3521 net cash used financing activity 37687 27749 400883 effect exchange rate change cash cash equivalent 1226 689 13041 net increase decrease cash cash equivalent 2855 12004 30369 cash cash equivalent beginning year 98688 110692 1049761 cash cash equivalent end year 101543 98688 1080130 see accompanying note consolidated financial statement shionogi annual report 2013 57 management shionogis business activity shionogis csr activity management system financial corporate information section consolidated financial statement note consolidated financial statement 1 basis preparation amounted 399 million 4244 thousand 150 million 1596 accompanying consolidated financial statement shionogi co thousand 154 million 1638 thousand 154 million 1638 ltd company consolidated subsidiary collectively thousand respectively group prepared basis accounting principle generally addition co subsidiary total 10 company accepted japan different certain respect changed fiscal yearend date june 30 december 31 application disclosure requirement international financial ever change effect consolidated financial result reporting standard compiled consolidated financial statement prepared company required financial b foreign currency translation instrument exchange act japan monetary asset liability denominated foreign currency preparing accompanying consolidated financial statement translated yen rate exchange effect balance certain reclassification made consolidated financial sheet date gain loss translation credited statement issued domestically order present format charged income familiar reader outside japan revenue expense item arising transaction denominated addition note consolidated financial statement foreign currency generally translated japanese yen rate include certain information required accounting exchange effect respective transaction date gain loss principle generally accepted japan presented herein addi foreign exchange credited charged income period tional information gain loss recognized financial reporting purpose certain reclassification previously reported amount asset liability overseas consolidated subsidiary made conform consolidated financial statement year translated yen rate exchange effect balance ended march 31 2012 2013 presentation reclassification sheet date revenue expense overseas consolidated sub effect consolidated net income net asset sidiaries translated yen average exchange rate component net asset excluding minority interest translated 2 summary significant accounting policy historical exchange rate adjustment resulting translating principle consolidation accounting investment foreign currency financial statement included deter affiliate mination net income reported translation adjustment accompanying consolidated financial statement include accumulated comprehensible income loss consolidated account company company controlled directly balance sheet indirectly company company company exer cis significant influence term operating financial c cash cash equivalent policy included consolidated financial statement cash cash equivalent include cash hand bank equity basis company applied equity method highly liquid investment maturity three month less investment three affiliate year ended march 31 2013 purchased investment affiliate accounted equity method carried cost shortterm investment investment security significant intercompany account transaction security classified three category trading security heldto eliminated consolidation maturity debt security security trading security consisting fiscal year end seventeen overseas consolidated subsidiary debt marketable equity security stated fair value gain december 31 different company sub loss realized unrealized charged income heldto sidiaries consolidated using financial statement maturity debt security stated amortized cost marketable securi year ended december 31 fiscal year end one overseas con tie classified security carried fair value solidated subsidiary june 30 year ended march 31 2013 change unrealized holding gain loss net applicable income consolidation purpose financial statement subsidiary tax reported separate component net asset nonmarketable prepared sixmonth period ended december 31 2012 security classified security carried cost determined result adjustment made significant transaction moving average method investment investment partnership taking place period january 1 march 31 stated amount net asset attributable ownership fiscal year ended march 31 2013 fiscal yearend date percentage company taiwan shionogi co ltd changed december 31 march 31 result change financial statement taiwan e derivative shionogi co ltd fiscal year ended march 31 2013 cover derivative carried fair value 15 month january 1 2012 march 31 2013 consoli dated financial result fiscal year ended march 31 f inventory 2013 period january 1 march 31 2012 net sale inventory principally stated lower cost determined operating income ordinary income income income tax average method net selling value taiwan shionogi co ltd eliminating intercompany transaction 58 shionogi annual report 2013 g property plant equipment leased asset n retirement benefit property plant equipment stated cost company defined benefit pension plan known cash depreciation property plant equipment calculated balance plan allows pension benefit fluctuate accordance straightline method estimated useful life respective market interest rate also lumpsum payment plan asset defined contribution pension plan certain domestic consolidated useful life property plant equipment summarized subsidiary lumpsum payment plan defined contribution follows pension plan addition certain consolidated subsidiary defined contribution pension plan certain case group may building structure 2 60 year also pay special retirement benefit subject actuarial machinery equipment vehicle 2 17 year calculation accrued retirement benefit provided based amount significant renewal addition capitalized cost mainte projected benefit obligation reduced pension plan asset nance repair charged income incurred fair value year end prior service cost amortized straightline method h lease period 10 year within estimated average remaining finance lease transaction transfer ownership depreci year service eligible employee ated nil residual value period lease contract using actuarial gain loss amortized year following year straightline method gain loss recognized principally straightline finance lease transaction entered march 31 method period 10 year within estimated aver 2008 transfer ownership continue accounted age remaining year service eligible employee operating lease provision sale return goodwill company provides reserve sale return amount goodwill amortized 20 year straightline method estimated loss expected incurred subsequent balance sheet date based product sale margin historical sale return ratio j research development expense computer certain consolidated subsidiary provide reserve sale return software amount estimated loss expected incurred subsequent research development expense charged income balance sheet date based total product sale historical sale incurred expenditure relating computer software developed return ratio internal use charged income incurred unless deemed contribute generation future income cost saving p hedge accounting expenditure capitalized asset amortized straightline company utilizes derivative transaction mitigating fluctua method respective estimated useful life generally period tion risk foreign currency asset liability forecast transaction 5 year interest rate loan hedging instrument forward foreign currency exchange contract currency option interest rate swap k income tax agreement hedged item foreign currency asset liability fore income tax calculated based taxable income charged cast transaction interest rate loan financial institution income accrual basis certain temporary difference exist gain loss derivative position designated hedge deferred taxable income income reported financial statement loss gain respective underlying hedged item purpose enter determination taxable income recognized interestrate swap meet certain condition different period accounted interest rate applied swap originally applied underlying debt special accounting treatment l allowance doubtful account forward foreign exchange contract meet certain criterion company consolidated subsidiary provide allowance accounted allocation method requires recognized doubtful account amount calculated based historical foreign currency receivables payable translated corre experience bad debt ordinary receivables plus additional sponding contract rate estimate probable specific bad debt customer experiencing company evaluates effectiveness hedging activity financial difficulty compared movement cash flow hedging instrument corresponding movement cash flow hedged item allowance employee bonus however regard forward foreign exchange contract allowance employee bonus provided estimated amount accounted allocation method interestrate swap bonus paid employee following year accounted special accounting treatment evaluation effectiveness omitted shionogi annual report 2013 59 management shionogis business activity shionogis csr activity management system financial corporate information section consolidated financial statement q distribution retained earnings effect change increase gross profit 540 million corporation law japan distribution retained earn 5744 thousand operating income 3255 million 34624 ings respect given financial period made resolution thousand ordinary income income income tax shareholder general meeting held subsequent close minority interest 3424 million 36422 thousand respectively financial period account period reflect year ended march 31 2013 corresponding amount distribution refer note 31 would recorded previous method 3 change accounting policy 4 accounting standard issued yet change depreciation method effective shionogi group changed method depreciation prop may 17 2012 accounting standard board japan asbj erty plant equipment straightline method effective year issued accounting standard retirement benefit asbj statement ended march 31 2013 declining balance method mainly 26 guidance accounting standard retirement ben applied past efits asbj guidance 25 replace accounting standard third mediumterm business plan fiscal 2010 retirement benefit issued business account shionogi group implementing fundamental strategy achieve ing council 1998 effective date april 1 2000 steady growth transitioning former organization mainly related practical guidance followed partial amendment corresponding product experienced rapid growth soon time time 2009 launch new one focusing eight strategic product standard require entity recognize overfunded expected achieve stable longterm earnings addition underfunded status defined benefit pension plan asset shionogi group pursuing fundamental strategy establish greater liability consolidated balance sheet actuarial gain loss presence north america europe asia aiming globalization prior service cost recognized part pension expense new drug development recognized part comprehensive income purpose expanding sale eight strategic product amount recognized accumulated comprehensive mentioned shionogi group completed consolidating income prior period recognized consolidated state strengthening manufacturing facility constructing ment income current period component pension benefit plant solid preparation well strengthening tablet granu expense treated reclassification adjustment lation facility addition shionogi group expects sale retirement benefit obligation attributed period eight strategic drug first time accounted benefit formula basis straightline method calcu 50 net sale year ended march 31 2013 account lation method discount rate shall changed higher percentage future addition consolidated subsidiary accounting standard related guidance effective established united kingdom shionogi ltd began operation end fiscal year beginning april 1 2013 however year ended march 31 2013 resulted comple amendment calculation method retirement benefit obliga tion establishing sale structure shionogi group north tion service cost applied effective april 1 2014 america europe asia result shionogi group reviewed company currently evaluating effect modifica method depreciation property plant equipment changed tions consolidated result operation financial straightline method following reason reflect sub position stance shionogi group operation appropriately 5 u dollar amount 1 shionogi group formerly focused product experi translation yen amount u dollar amount included enced rapid growth soon launch enabled comparatively solely convenience matter arithmetic computation faster cost recovery facility investment transition 9401 us100 approximate rate exchange effect focus eight strategic product expected generate march 31 2013 translation construed repre longterm earnings facility utilization also expected sentation yen could could future consistent stable converted u dollar rate 2 overseas subsidiary principally applied straightline 6 shortterm investment investment method property plant equipment shionogi group security therefore required unify accounting policy appli 1 information heldtomaturity debt security march 31 cation straightline method effectively efficiently allo 2013 2012 omitted due immateriality cate resource among unified network base japan north america europe asia contribute construction maintenance operation global research development production sale organization 60 shionogi annual report 2013 2 marketable security classified security march 31 2013 7 inventory 2012 follows inventory march 31 2013 2012 follows million yen thousand million yen u dollar 2013 2013 2012 2013 gross gross acquisition unrealized unrealized carrying merchandise 5076 4230 53994 cost gain loss value finished good 16108 14871 171344 equity security 78322 23729 341 101710 semifinished good government bond work process 19372 19601 206063 municipal bond etc 14853 877 2 15728 raw material supply 8772 11419 93309 security 87435 617 88052 49328 50121 524710 180610 25223 343 205490 million yen 8 shortterm bank loan longterm debt 2012 annual average interest rate applicable shortterm bank loan gross gross march 31 2013 17 acquisition unrealized unrealized carrying cost gain loss value longterm debt march 31 2013 2012 consisted equity security 28260 11759 1673 38346 following thousand government bond million yen u dollar municipal bond etc 14850 425 15275 2013 2012 2013 security 5051 515 5566 unsecured loan bank 48161 12699 1673 59187 financial institution due 2019 average interest rate thousand u dollar 20 41528 63000 441740 2013 unsecured bond due 2012 gross gross acquisition unrealized unrealized carrying average interest rate cost gain loss value 08 10000 equity security 833124 252409 3627 1081906 unsecured bond due 2014 average interest rate government bond 11 20000 20000 212744 municipal bond etc 157994 9329 22 167301 61528 93000 654484 security 930061 6563 936624 less current portion 31500 24000 335071 1921179 268301 3649 2185831 30028 69000 319413 3 proceeds sale gross realized gain loss security year ended march 31 2013 2012 sum unsecured loan included loan without interest amount marized follows 28 million 298 thousand thousand million yen u dollar aggregate annual maturity longterm debt subsequent 2013 2012 2013 march 31 2013 summarized follows proceeds sale 3843 4179 40879 thousand gross realized gain 1019 153 10839 year ending march 31 million yen u dollar gross realized loss 2014 31500 335071 2015 20000 212743 2016 28 298 4 loss devaluation investment security 2019 thereafter 10000 106372 loss devaluation investment security recorded securi 61528 654484 tie whose fair value declined 30 decline deemed irrecoverable considering financial position security issuer factor 9 pledged asset company recognized loss devaluation investment asset pledged collateral march 31 2013 follows security 124 million 1319 thousand 426 million thousand million yen u dollar year ended march 31 2013 2012 respectively 2013 2013 cash cash equivalent 7 74 shionogi annual report 2013 61 management shionogis business activity shionogis csr activity management system financial corporate information section consolidated financial statement corresponding liability secured collateral march 31 movement number stock option vesting 2011 2013 follows 2012 plan 2012 plan company year thousand ended march 31 2013 summarized follows million yen u dollar 2011 plan 2012 plan 2013 2013 number option number option deposit received employee outstanding april 1 2012 52200 included current liability 7 74 vested 79100 exercised 7200 10 contingent liability forfeited company contingently liable guarantee employee outstanding march 31 2013 45000 79100 housing loan 10 million 106 thousand march 31 2013 11 shareholder equity unit price stock option 2011 2012 plan corporation law japan law provides amount company year ended march 31 2013 summarized equal 10 amount disbursed distribution capital follow 2011 plan 2012 plan surplus capital reserve retained earnings yen u dollar yen u dollar legal reserve transferred capital reserve legal unit price stock option reserve respectively sum capital reserve legal exercise price march reserve equal 25 capital stock account distribution 31 2013 1 001 1 001 made time resolution shareholder board average market price per director certain condition met share upon exercise 1034 1100 company legal reserve included retained earnings march estimated fair value 31 2013 2012 amounted 5388 million 57313 thousand unit price grant date 1129 1201 916 974 law upon issuance sale new share common stock entire amount proceeds required valuation method estimating fair value blacksholes accounted common stock although company may resolu model major assumption used follows tion board director account amount exceeding major assumption note 2012 plan onehalf proceeds sale new share additional paidin estimated volatility 3143 capital included capital surplus estimated remaining period b 66 year accordance law stock option plan two director estimated dividend c 40 per share eleven corporate officer company approved annual riskfree rate 0344 general meeting shareholder company held june 27 2012 2012 plan term plan 79100 share estimated volatility computed actual stock price common stock granted vested immediately option company period december 2005 july 2012 became exercisable july 13 2012 scheduled expire b estimated remaining period average period stock option july 12 2042 stock option expense 72 million 766 thousand holder retirement accordance internal regulation included selling general administrative expense c estimated dividend calculated actual amount year ended march 31 2013 year ended march 31 2012 way stock option plan three director nine riskfree rate based average rate compound corporate officer company approved annual general interest yield bond redemption date within three meeting shareholder company held june 24 2011 month estimated remaining period statistic data 2011 plan term plan 52200 share longterm interestbearing government bond published common stock granted vested immediately option japan security dealer association became exercisable july 12 2011 scheduled expire july 11 2041 stock option expense 52 million included difficult reasonably estimate number stock selling general administrative expense year ended march option forfeited estimation reflects actual 31 2012 number forfeited stock option 62 shionogi annual report 2013 movement issued share common stock treasury stock c risk management financial instrument year ended march 31 2013 2012 summarized monitoring credit risk risk customer counterparties follows may default number share accordance procedure determined company 2013 accounting finance department related section com april 1 2012 increase decrease march 31 2013 pany periodically monitor condition major customer manage issued share collection due date balance customer try identify common stock 351136165 351136165 credit risk customer worsening financial condition treasury stock 16240245 2958 7200 16236003 early stage mitigate risk consolidated subsidiary perform similar credit management accordance internal rule number share company 2012 april 1 2011 increase decrease march 31 2012 company enters derivative transaction financial insti issued share tutions high credit rating mitigate counterparty risk common stock 351136165 351136165 maximum amount credit risk balance sheet date repre treasury stock 16237775 2470 16240245 sented carrying value financial asset exposed credit risk company purchased 2958 share 2470 share common ii monitoring market risk risk arising fluctuation stock shareholder fractional share less one unit foreign exchange rate interest rate others year ended march 31 2013 2012 respectively company utilizes forward foreign currency exchange contract company disposed 7200 share common stock exer currency option contract hedging mitigate fluctuation risk identi cise subscription right share year ended march 31 fied foreign currency trade receivables payable fore 2013 casted transaction company also utilizes interest rate swap agreement control fluctuation risk interest rate loan 12 financial instrument company continuously review security holding monitoring 1 overview periodically market financial condition security issuer policy financial instrument company business relationship group also company obtains necessary funding principally bank borrowing review holding condition security heldtomaturities bond issuance business plan main business evaluating relationship company production sale pharmaceutical temporary surplus fund accounting finance department enters derivative trans managed lowrisk financial asset derivative utilized mitigat action rule determined company utilizes ing risk described later part note utilized ward foreign exchange contract currency option contract speculative purpose interestrate swap agreement within normal range transaction accounting finance department manages information b type financial instrument related risk transaction reporting periodically board director meet trade receivables note account receivable exposed ings consolidated subsidiary utilize derivative transaction credit risk customer trade receivables denominated foreign currency exposed fluctuation risk foreign currency iii monitoring liquidity risk risk group may able shortterm investment investment security exposed meet obligation scheduled due date fluctuation risk market price company manages liquidity risk accounting finance trade payable note account payable due within almost department preparing updating cash flow plan timely basis one year certain trade payable denominated foreign currency keeping necessary fund based report prepared import raw material exposed fluctuation risk department eign currency loan bond utilized principally necessary financing business plan maturity date due supplementary explanation estimated fair value six year longest subsequent march 31 2013 financial instrument derivative transaction made hedging foreign currency fluc fair value financial instrument based quoted market tuation risk trade receivables trade payable forecasted transac price available quoted market price available fair tions denominated foreign currency using forward foreign value reasonably estimated since various assumption factor exchange contract currency option contract hedging reflected estimating fair value different assumption factor interest rate fluctuation risk loan using interest rate swap agree could result different fair value addition notional amount ments refer hedge accounting note 2 summary significant derivative note 28 necessarily indicate market risk accounting policy information hedge accounting derivative transaction hedging instrument hedged item hedging policy forth shionogi annual report 2013 63 management shionogis business activity shionogis csr activity management system financial corporate information section consolidated financial statement million yen e concentration credit risk 2012 march 31 2013 2012 59 percent 56 percent respectively carrying value fair value difference outstanding trade receivables represented receivables due cash cash equivalent 98688 98688 specific largescale customer note account receivabletrade affiliate 65568 65548 20 2 fair value financial instrument shortterm investment carrying value financial instrument consolidated balance investment security sheet march 31 2013 2012 fair value differ affiliate 60389 60389 ences shown following table following table total asset 224645 224625 20 include financial instrument extremely difficult deter note account payable mine fair value affiliate 1231 1231 million yen trade 7382 7382 2013 current portion longterm debt carrying value fair value difference current portion longterm loan 14000 14005 5 cash cash equivalent 101543 101543 current portion longterm bond 10000 10009 9 note account accrued income tax 9891 9891 receivabletrade affiliate 67909 67902 7 longterm debt shortterm investment investment security bond payable 20000 20360 360 affiliate 70776 70776 longterm loan 49000 49866 866 total asset 240228 240221 7 total liability 111504 112744 1240 note account payable derivative transaction 228 228 affiliate 1434 1434 trade 9301 9301 thousand u dollar shortterm bank loan 7500 7500 2013 current portion longterm debt carrying value fair value difference current portion longterm loan 31500 31698 198 cash cash equivalent 1080130 1080130 accrued income tax 1079 1079 note account receivabletrade affiliate 722359 722285 74 longterm debt shortterm investment bond payable 20000 20211 211 investment security longterm loan 10028 10730 702 affiliate 752856 752856 total liability 80842 81953 1111 total asset 2555345 2555271 74 derivative transaction 726 726 note account payable affiliate 15254 15254 trade 98936 98936 shortterm bank loan 79779 79779 current portion longterm debt current portion longterm loan 335071 337177 2106 accrued income tax 11478 11478 longterm debt bond payable 212743 214987 2244 longterm loan 106670 114137 7467 total liability 859931 871748 11817 derivative transaction 7723 7723 asset liability arising derivative transaction shown net value amount parenthesis representing net liability position method determine fair value financial instrument short term investment investment security derivative transaction 64 shionogi annual report 2013 asset c redemption schedule monetary asset marketable securi cash cash equivalent tie maturity march 31 2013 2012 since item settled short time period carrying million yen value approximates fair value 2013 note account receivabletrade affiliate due due 1 year 5 year fair value account receivable require longer period due due collection determined based present value group 1 year less 5 year 10 year 10 year receivables classified collection term computed discount rate cash cash equivalent 101541 consideration credit risk corresponding collection term note account receivabletrade since account receivable settled short time period affiliate 67455 454 carrying value approximates fair value shortterm investment shortterm investment investment security investment security regard shortterm investment investment security government fair value debt security determined quoted market price municipal bond 2000 12000 price offered financial institution equity security bond 20 determined quoted market price refer note 6 shortterm security maturity 2432 846 investment investment security information security holding purpose total 173448 454 12846 million yen liability 2012 n otes account payable shortterm bank loan accrued due due income tax 1 year 5 year since item settled short time period carrying due due 1 year less 5 year 10 year 10 year value approximates fair value cash cash equivalent 98688 current portion longterm loan longterm loan note account fair value current portion longterm loan longterm receivabletrade loan based present value total principal interest affiliate 64154 1414 discounted estimated interest rate applied similar new shortterm investment investment security loan made longterm loan floating interest hedged interest rate swap agreement accounted loan fixed government municipal bond 4000 2000 8000 interest rate fair value longterm loan based bond 20 present value total principal interest cash flow security interest rate swap agreement discounted reasonably estimated maturity 2327 739 interest rate applied similar new loan made total 169189 3414 8739 bond payable fair value bond payable based quoted market price thousand u dollar 2013 derivative transaction due due 1 year 5 year please refer note 28 derivative transaction due due 1 year less 5 year 10 year 10 year b f inancial instrument extremely difficult determine cash cash equivalent 1080108 fair value note account thousand receivabletrade million yen u dollar affiliate 717530 4829 2013 2012 2013 shortterm investment unlisted equity security 56318 9476 599064 investment security government municipal bond 21274 127646 quoted market price available extremely dif bond 213 ficult determine fair value financial instrument security included preceding table maturity 25869 8999 total 1844994 4829 136645 shionogi annual report 2013 65 management shionogis business activity shionogis csr activity management system financial corporate information section consolidated financial statement 13 impairment loss fixed asset effective tax rate year ended march 31 2013 2012 fixed asset business use grouped based corresponding differ statutory tax rate following reason management segment product line asset available rent 2013 2012 idle asset grouped individually statutory tax rate 380 406 impairment loss fixed asset year ended march 31 2013 expense deductible income tax purpose 08 05 summarized follows dividend taxable income tax purpose 07 05 million thousand amortization goodwill 21 28 yen u dollar tax credit 01 125 location use classification 2013 2013 inhabitant per caput tax 02 03 united state business ethical america pharmaceutical difference statutory tax rate overseas product goodwill 26372 280523 subsidiary 32 27 united state exclusive marketing consolidation adjustment sale america right ethical consolidated subsidiary 11 12 pharmaceutical marketing decrease deferred tax asset due change product right 14464 153856 statutory tax rate 01 05 increase valuation allowance 410 upon concluding agreement concerning antihiv drug viiv loss valuation investment affiliate 718 healthcare ltd viiv located united kingdom company effect organization restructuring 266 considered reallocating management resource u operation 03 01 found indication impairment marketing right others effective tax rate 146 347 associated product shionogi inc whollyowned subsidiary united state america sell shionogi also found indication tax effect temporary difference march 31 2013 2012 impairment goodwill due change grouping general gave rise significant deferred tax asset liability prescription drug business u operation result shionogi presented group recognized impairment loss equivalent difference thousand book value recoverable value impaired asset million yen u dollar 2013 2012 2013 impairment loss fixed asset year ended march 31 2012 deferred tax asset summarized follows tax loss carry forward 18921 4875 201266 million research development yen cost 14783 7191 157249 location use classification 2012 accrued expense united state inprocess research current liability 3836 2821 40804 america development loss revaluation expense investment security 2904 557 30890 compound developing allowance employee pharmaceutical asset 1557 bonus 2685 2563 28561 provision sale return 2438 2034 25934 retirement benefit 193 304 2053 company concluded future value use existed accrued enterprise tax 46 882 489 certain pharmaceutical compound recorded 4647 4806 49431 process research development expense included asset valuation allowance 14463 405 153845 result group reduced related carrying value inprocess research development expense included asset recov total deferred tax asset 35990 25628 382832 erable value zero recognized impairment loss deferred tax liability unrealized gain security 8876 4269 94416 14 income tax prepaid pension cost 5537 4731 58898 income tax applicable company domestic consoli investment security 1492 2263 15871 dated subsidiary comprise corporation tax inhabitant tax reserve advanced enterprise tax aggregate resulted statutory tax rate depreciation fixed approximately 380 406 year ended march 31 asset 1388 1423 14764 2013 2012 4688 5390 49867 overseas subsidiary subject income tax total deferred tax liability 21981 18076 233816 respective country operate net deferred tax asset 14009 7552 149016 66 shionogi annual report 2013 15 retirement benefit 16 cost sale following table set forth retirement benefit obligation plan cost sale included loss devaluation inventory 1692 asset funded status group defined benefit pension million 17998 thousand 1143 million year ended plan march 31 2013 2012 march 31 2013 2012 respectively thousand million yen u dollar 2013 2012 2013 17 research development expense research development expense included selling general retirement benefit obligation end year 86671 82912 921934 administrative expense year ended march 31 2013 2012 fair value plan asset amounted 53021 million 563993 thousand 53599 end year 85763 78629 912275 million respectively unfunded status 908 4283 9659 unrecognized actuarial loss 18460 21487 196362 18 loss sale fixed asset unrecognized prior service loss sale fixed asset year ended march 31 2013 cost 1275 3188 13562 follows net retirement benefit thousand obligation 16277 14016 173141 million yen u dollar prepaid pension cost 25272 22809 268822 2013 2013 accrued retirement benefit building structure 205 2181 employee 8995 8793 95681 land 58 617 furniture fixture 66 702 table include special retirement benefit expense total 329 3500 paid please refer note 21 special retirement benefit expense 19 loss disaster loss disaster year ended march 31 2013 represented component retirement benefit expense year ended estimated amount covered insurance connection march 31 2013 2012 outlined follows disposal inventory damaged fire supplier shionogi inc thousand 2011 million yen u dollar 2013 2012 2013 company recorded loss disaster connection service cost 1964 1919 20891 impact great east japan earthquake year ended march interest cost 1658 1696 17637 31 2012 expected return plan asset 2040 2140 21700 20 litigation settlement amortization actuarial loss 2442 4048 25976 litigation settlement principally represents settlement amortization prior service reached shionogi inc lupin ltd cost 1913 2420 20349 contribution defined 21 special retirement benefit expense contribution pension plan 1113 896 11839 expense attributable retirement benefit expense incurred retirement benefit expense 3224 3999 34294 shionogi inc assumption used accounting defined benefit pension 22 business structure improvement expense plan year ended march 31 2013 2012 follows business structure improvement expense represents cost related 2013 2012 reorganization shionogi inc discount rate 12 20 expected rate return plan asset 28 28 end fiscal year ended march 31 2013 company subsidiary revised discount rate 20 applied beginning fiscal year result company deter mined change discount rate would significantly affect amount retirement benefit obligation therefore changed discount rate 12 shionogi annual report 2013 67 management shionogis business activity shionogis csr activity management system financial corporate information section consolidated financial statement 23 consolidated statement thousand u dollar carrying value fair value comprehensive income april 1 2012 net change march 31 2013 march 31 2013 following table present analysis comprehensive 57356 4744 52612 207776 income year ended march 31 2013 2012 thousand million yen u dollar carrying value table presented amount 2013 2012 2013 acquisition cost less accumulated depreciation accumulated net unrealized holding gain impairment loss security fair value march 31 2013 primarily calculated based real amount arising year 13792 5542 146708 estate appraisal standard case amount adjusted reclassification adjustment gain loss included net using index method income 860 177 9148 tax effect 12932 5719 137560 25 related party transaction tax effect 4606 1723 48995 principal transaction subsidiary related party total 8326 3996 88565 year ended march 31 2013 2012 summarized follows deferred loss gain hedge amount arising year 218 527 2319 transaction director thousand reclassification adjustment million yen u dollar gain included net income 281 269 2989 2013 2012 2013 tax effect 499 258 5308 shunjusha co ltd tax effect 190 110 2021 rent receivedland office total 309 148 3287 building 51 51 542 translation adjustment rent expensebuilding 166 147 1766 amount arising year 15586 1766 165791 management fee leased reclassification adjustment property 3 3 32 gain included net income 679 7223 tax effect 14907 158568 shunjusha co ltd directly owned director relative tax effect director company engaged real estate leasing total 14907 1766 158568 business percentage voting right owned two people comprehensive income 22924 2378 243846 100 march 31 2013 shunjusha co ltd located chuoku osaka capital amount 100 million 1064 thou 24 investment rental property sand 701 million march 31 2013 2012 respectively group owns office building including land lease mainly price related party transaction determined tokyo area reference market value transaction made area rental income net related expense relevant real estate property amounted 1101 million 11711 thousand 963 outstanding balance connection related party million year ended march 31 2013 2012 rental transaction outlined march 31 2013 2012 income principally recorded net sale rental expense principally recorded cost sale 26 supplementary cash flow information carrying value consolidated balance sheet correspond 1 significant noncash transaction ing fair value property follows october 31 2012 company received share viiv valued million yen 53718 million 571407 thousand contribution kind carrying value fair value involving transfer equity ownership shionogiviiv healthcare april 1 2012 net change march 31 2013 march 31 2013 lp equitymethod affiliate 5392 446 4946 19533 million yen carrying value fair value april 1 2011 net change march 31 2012 march 31 2012 5643 251 5392 19257 68 shionogi annual report 2013 2 summary asset liability former financial data used computation basic net income per unconsolidated subsidiary became newly share diluted net income per share year ended march 31 consolidated subsidiary due acquisition share 2013 2012 table summarized follows september 19 2011 company acquired share co thousand million yen u dollar initially consolidated account co consolidated subsid 2013 2012 2013 iaries december 31 2011 sixmonth period information used computation ended asset liability included consolidation sum basic net income per share marized follows net income 66728 27102 709797 million yen 2012 thousand share current asset 5386 2013 2012 noncurrent asset 5634 weightedaverage number share goodwill 8196 common stock outstanding 334900 334897 current liability 1461 increase common stock 125 52 noncurrent liability 626 share subscription right 125 52 minority interest 3026 acquisition cost 14103 financial data used computation net asset per share cash cash equivalent co 1336 march 31 2013 2012 table summarized follows account payable 128 thousand cash disbursement 12639 million yen u dollar 2013 2012 2013 total net asset 423633 347198 4506255 27 amount per share amount deducted total amount per share year ended march 31 2013 net asset 3522 2982 37464 2012 follows amount attributable share yen u dollar subscription right total net 2013 2012 2013 asset 123 59 1308 net income 19925 8093 212 amount attributable minority interest total net asset 3399 2923 36156 diluted net income 19917 8091 212 net asset used calculation net asset 125444 102783 1334 net asset per share 420111 344216 4468791 cash dividend applicable year 4200 4000 045 thousand share 2013 2012 net income per share computed based net income attribut number share used calculation net able shareholder common stock weightedaverage asset per share 334900 334895 number share common stock outstanding year diluted net income per share computed based net income attributable shareholder common stock weighted average number common share outstanding year giving effect dilutive potential share common stock issued upon exercise stock option amount per share net asset computed based number share common stock outstanding year end cash dividend per share represent cash dividend proposed board director applicable respective year together interim cash dividend paid shionogi annual report 2013 69 management shionogis business activity shionogis csr activity management system financial corporate information section consolidated financial statement 28 derivative transaction 1 derivative transaction hedge accounting apply information derivative transaction hedge accounting apply omitted since outstanding derivative position qualified hedge accounting 2 derivative transaction hedge accounting applies 1 currencyrelated transaction million yen 2013 contract value portion notional transaction principal hedged item notional amount amount one year fair value forward foreign currency exchange contract selling usd forecasted transaction 6059 926 forward foreign currency exchange contract buying usd forecasted transaction 6059 309 currency option selling call option usd forecasted transaction 1731 157 currency option buying put option usd forecasted transaction 1731 48 million yen 2012 contract value portion notional transaction principal hedged item notional amount amount one year fair value forward foreign currency exchange contract selling usd forecasted transaction 22996 5749 154 forward foreign currency exchange contract buying usd forecasted transaction 1643 18 currency option buying call option usd forecasted transaction 21354 48 currency option selling put option usd forecasted transaction 21354 89 currency option selling call option usd forecasted transaction 9034 20 currency option buying put option usd forecasted transaction 9034 34 thousand u dollar 2013 contract value portion notional transaction principal hedged item notional amount amount one year fair value forward foreign currency exchange contract selling usd forecasted transaction 64451 9850 forward foreign currency exchange contract buying usd forecasted transaction 64451 3287 currency option selling call option usd forecasted transaction 18413 1670 currency option buying put option usd forecasted transaction 18413 511 note 1 fair value calculated based price provided counterparty financial institution 2 currency option contract zerocost option premium received paid 70 shionogi annual report 2013 2 interest raterelated transaction million yen 2013 contract value portion notional method hedge accounting transaction principal hedged item notional amount amount one year fair value special accounting treatment interest rate swap shortterm bank pay fixedreceive floating loan longterm debt 25000 25000 million yen 2012 contract value portion notional method hedge accounting transaction principal hedged item notional amount amount one year fair value special accounting treatment interest rate swap pay fixedreceive floating longterm debt 25000 25000 thousand u dollar 2013 contract value portion notional method hedge accounting transaction principal hedged item notional amount amount one year fair value special accounting treatment interest rate swap shortterm bank pay fixedreceive floating loan longterm debt 265929 265929 since interest rate swap accounted special accounting treatment refer note 2p fair value included shortterm bank loan longterm debt disclosed note 12 financial instrument 29 segment information 2 geographical information 1 segment information year ended march 31 2013 net sale 2012 thousand million yen u dollar group operates single business segment related prescription 2013 2012 2013 drug involving research development purchasing manufacturing japan 185227 184085 1970291 distribution related business prescription drug analy europe 64730 65884 688544 s sale product evaluation performance group com united kingdom 63027 65096 670429 panies performed decision business strategy allocation north america 22960 11358 244229 management resource especially allocation research develop united state america 22957 11353 244197 ment expense made groupwide basis therefore disclosure 9987 5948 106233 segment information year ended march 31 2013 2012 total 282904 267275 3009297 omitted 2 related information net sale information classified country region 1 information sale product service based location customer main country region amount sale third party one type product included category follows service single segment accounted 90 net 1 europe united kingdom switzerland germany sale consolidated statement income year ended 2 north america united state america march 31 2013 2012 information sale product 3 asia service omitted b property plant equipment balance property plant equipment located japan accounted 90 balance property plant equipment recognized consolidated balance sheet march 31 2013 2012 information property plant equipment geographical segment omitted shionogi annual report 2013 71 management shionogis business activity shionogis csr activity management system financial corporate information section consolidated financial statement 3 information major customer 4 date equity ownership transfer net sale october 31 2012 thousand million yen u dollar related segment customer name 2013 2012 2013 name 5 outline transaction including legal form suzuken co ltd 65746 68230 699351 pharmaceutical contribution inkind astrazeneca uk limited 62671 64463 666642 pharmaceutical viiv received equity ownership jv return shionogi group received share viiv toho pharmaceutical co ltd 39246 36915 417466 pharmaceutical 2 outline accounting treatment transfer accounted transfer asset exchange 3 group primarily engaged research development mer share transferee excluding business divestiture based chandising manufacturing marketing ethical pharmaceutical accounting standard business divestiture asbj statement related business 7 december 26 2008 guidance accounting standard accordingly information regarding impairment loss fixed asset business combination accounting standard business divesti amount amortization goodwill remaining balance gain tures asbj guidance 10 december 26 2008 negative goodwill reportable segment march 31 2013 2012 year ended omitted 1 gain exchange 40434 million 430103 thousand shionogi group recognized difference carrying 30 business combination value equity position jv market value fair value transfer equity ownership shionogiviiv healthcare lp 10 percent equity position viiv gain exchange investment 1 summary equity ownership transfer security 1 name equity ownership transferee viiv healthcare ltd 2 carrying value transferred equity ownership investment security 7278 million 77417 thousand 2 detail transferred equity ownership shionogi group transferred equity ownership 50 percent shion 3 name corresponding reportable segment ogiviiv healthcare lp equitymethod affiliate prescription drug jv jv established joint venture agreement shionogi group viiv united kingdom 4 income associated transfer equity ownership reported consolidated statement income 3 reason transfer equity ownership fiscal year ended march 31 2013 follows shionogi group established jv purpose developing thousand million yen u dollar marketing product development focused hiv integrase net sale inhibitor dolutegravir generic name shionogi code s349572 dtg operating income 3515 37390 related product including combination dtg inte ordinary income 2966 31550 grase inhibitor s265744 s247303 however combination treatment various drug expected mainstream treating hiv therefore management jv 31 subsequent event dtg single asset would face difficulty addition following distribution retained earnings company shionogi group acquired sciele pharma inc currently shionogi reflected accompanying consolidated financial inc 2008 jv necessary establishing base sale statement year ended march 31 2013 approved united state originally expected jv formed shareholder meeting held june 26 2013 million thousand furthermore shionogi inc marketing model aligned yen u dollar selling hiv drug accordingly changing circumstance time cash dividend 2200 us023 per share 7368 78375 led shionogi group initiate discussion creating new framework acquisition clinical trial data required ndas completed october 2012 submission ndas dtg planned 2012 shionogi group concluded agreement transferred equity jv viiv exchange 10 per cent state viiv information purpose ndas dtg submitted december 2012 72 shionogi annual report 2013 independent auditor report board director shionogi co ltd audited accompanying consolidated financial statement shionogi co ltd consolidated subsidiary comprise consolidated balance sheet march 31 2013 consolidated statement income comprehensive income change net asset cash flow year ended summary significant accounting policy explanatory information expressed japanese yen management responsibility consolidated financial statement management responsible preparation fair presentation consolidated financial statement accordance accounting principle generally accepted japan designing operating internal control management determines necessary enable preparation fair presentation consolidated financial statement free material misstatement whether due fraud error auditor responsibility responsibility express opinion consolidated financial statement based audit conducted audit accordance auditing standard generally accepted japan standard require plan perform audit obtain reasonable assurance whether consolidated financial statement free material misstatement audit involves performing procedure obtain audit evidence amount disclosure consolidated financial statement procedure selected depend auditor judgment including assessment risk material misstatement consolidated financial statement whether due fraud error purpose audit consolidated financial statement express opinion effectiveness entity internal control making risk assessment auditor considers internal control relevant entity preparation fair presentation consolidated financial statement order design audit procedure appropriate circumstance audit also includes evaluating appropriateness accounting policy used reasonableness accounting estimate made management well evaluating overall presentation consolidated financial statement believe audit evidence obtained sufficient appropriate provide basis audit opinion opinion opinion consolidated financial statement referred present fairly material respect consolidated financial position shionogi co ltd consolidated subsidiary march 31 2013 consolidated financial performance cash flow year ended conformity accounting principle generally accepted japan convenience translation reviewed translation consolidated financial statement u dollar presented convenience reader opinion accompanying consolidated financial statement properly translated basis described note 5 june 26 2013 osaka japan shionogi annual report 2013 73 management shionogis business activity shionogis csr activity management system financial section corporate information shionogi group directory august 19 2013 major business location major consolidated subsidiary head office branch office shionogi pharma chemical co ltd 1 head office 22420 ebisuno hiraishi kawauchicho tokushima 7710132 japan 18 doshomachi 3chome chuoku osaka 5410045 japan tel 81886652312 tel 81662022161 fax 81662299596 shionogi analysis center co ltd 2 tokyo branch office 51 mishima 2chome settsu osaka 5660022 japan shionogi shibuya bldg 175 shibuya 2chome tel 81663817271 shibuyaku tokyo 1500002 japan saishin igaku co ltd tel 81334068111 shionogi doshomachi bldg 76 doshomachi 4chome chuoku osaka nagoya branch office 5410045 japan sky oasis sakae 9 shinsakaemachi 2chome tel 81662222876 nakaku nagoya aichi 4600004 japan shionogi techno advance research co ltd tel 81529578271 311 futabacho toyonaka osaka 5610825 japan fukuoka branch office tel 81663318605 shin kbc bldg 135 nagahama 1chome chuoku shionogi general service co ltd fukuoka city fukuoka 8100072 japan shionogi doshomachi bldg 76 doshomachi 4chome chuoku osaka tel 81927377750 5410045 japan sapporo branch office tel 81662270815 nissay sapporo bldg 11 kitasanjonishi 4chome 7 taiwan shionogi co ltd chuoku sapporo hokkaido 0600003 japan 4f no2 sec 2 nanking east road taipei 10457 taiwan tel 81112522290 tel 886225516336 development office 8 shionogi inc global development office 300 campus drive florham park nj 07932 usa 12f hankyu terminal bldg 14 shibata 1chome tel 19739666900 kitaku osaka 5300012 japan ezose science inc tel 81664855055 25 riverside drive pine brook nj 07058 usa laboratory tel 18629261950 3 shionogi pharmaceutical research center 9 co pharmaceutical technology holding limited 11 futabacho 3chome toyonaka osaka 5610825 japan 91112 silvercord tower 2 30 canton road tel 81663318081 tsim sha tsui kowloon hong kong tel 85228060109 shionogi innovation center drug discovery kita 21 nishi 11 kitaku sapporo hokkaido 0010021 japan 0 shionogi limited tel 81117004700 3 shortlands hammersmith london w6 8da united kingdom tel 442036098660 plant beijing shionogi pharmaceutical technology limited 4 settsu plant room 2443 level 24 tower 3 china central place 77 jianguo road 51 mishima 2chome settsu osaka 5660022 japan chaoyang district beijing 100025 tel 81663817341 tel 861085872212 5 kanegasaki plant 7 moriyama nishine kanegasakicho isawagun iwate 0294503 japan tel 81197445121 administration office 6 kuise site 13 kuise terajima 2chome amagasaki hyogo 6600813 japan tel 81664011221 5 aburahi facility 1405 gotanda kokacho koka shiga 5203423 japan 6 tel 81748883281 3 4 distribution center 2 shionogi osaka distribution center mitsubishi logistics corporation ibaraki 3 distribution center 1 17 fujinosato 2chome ibaraki osaka 5670054 japan tel 81726404856 shionogi tokyo distribution center mitsubishi logistics corporation misato 2 distribution center 117 hikoe 2chome misato saitama 3410058 japan 0 tel 81489100158 overseas office outside japan shionogi co ltd taipei office 8 4f 2 sec 2 nanking east road taipei 10457 taiwan 7 tel 886225516336 9 shionogi co ltd shanghai office far east international plaza 3f 318a 319 xian xia road shanghai 200051 people republic china tel 862162351311 74 shionogi annual report 2013 corporate information march 31 2013 company name shionogi co ltd number employee consolidated 6082 established march 17 1878 category business marketing manufacturing drug incorporated june 5 1919 type business manufacturing distribution paidin capital 21280 million pharmaceutical diagnostic reagent website httpwwwshionogicojpindex_ehtml medical device etc head office 18 doshomachi 3chome chuoku fiscal yearend march 31 osaka 5410045 japan net sale consolidated 282904 million tel 81662022161 year ended march 31 2013 fax 81662299596 stock security listing tokyo 4507 transfer agent sumitomo mitsui trust bank limited common stock authorized 1000000000 share stock transfer agency department issued 351136165 share 533 kitahama 4chome chuoku number shareholder 37751 osaka 5410041 japan major shareholder number percentage name share total share thousand master trust bank japan ltd trustee 23593 704 sumitomo life insurance company 18604 555 japan trustee service bank ltd trustee 16855 503 jp morgan chase bank 385147 12066 360 nippon life insurance company 10511 313 ssbt od05 omnibus account treaty client 9743 290 japan trustee service bank ltd trustee sumitomo mitsui trust bank ltd ii retirement benefit 9485 283 sumitomo mitsui banking corporation sumitomo mitsui banking corporation 6564 196 state street bank trust company 505225 4600 137 mellon bank na agent client mellon omnibus u pension 4349 129 note 1 company hold 16236003 share treasury stock however shareholding included list top10 shareholder 2 percentage total share calculated proportion 334900162 share total number issued share less treasury stock stock price range trading volume tokyo stock exchange monthly stock price range ncommon stock price range yen topix price index close 3000 2500 2000 1500 1000 500 0 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 09 10 11 12 13 monthly trading volume million share 60 40 20 0 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 09 10 11 12 13 shionogi annual report 2013 75 annual report 2013 printed japan vegetable oil ink fsc certified paper